{\rtf1\deflang1033\deflangfe1033\margl720\margr720\margt360\margb360{\stylesheet{\fs20\lang1033\snext0 Normal;}
{\s1\sb240\keepn{\*\pn \pnlvl1\pndec\pnprev1\pnstart1\pnsp144}\b\f0\fs30\lang1033 \sbasedon0\snext0 heading 1;}
{\s2\sb200\keepn{\*\pn \pnlvl2\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs26\lang1033 \sbasedon0\snext0 heading 2;}
{\s3\sb180\keepn{\*\pn \pnlvl3\pndec\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 3;}
{\s4\sb160\keepn{\*\pn \pnlvl4\pnucltr\pnprev1\pnstart1\pnsp144{\pntxtb.}}\b\f0\fs22\lang1033 \sbasedon0\snext0 heading 4;}
{\s5\sb140\keepn{\*\pn \pnlvl5\pncltr\pnprev1\pnstart1\pnsp144}\b\f0\fs20\lang1033 \sbasedon0\snext0 heading 5;}
{\s6\tqc\lang1033\sbasedon0\snext6 footer;}
{\*\cs16 \additive\super\sbasedon10 footnote reference;}
{\*\cs18 \additive\sbasedon10 page number;}}
{\fonttbl{\f0\fnil Times New Roman;}{\f1\fnil Courier New}{\f2005\fnil Courier New;}{\f2010\fnil Wingdings;}{\f2020\fnil Webdings;}{\f2\fnil Arial;}{\f3\fnil Arial;}{\f4\fnil LucidaHandwriting;}{\f5\fnil Symbol;}{\f6\fnil Symbol;}{\f7\fnil Ferdsch;}{\f30\fnil Myriad Cn Semibold;}{\f31\fnil Myriad Roman;}{\f50\fnil Courier New;}{\f51\fnil Times New Roman;}{\f52\fnil Arial;}{\f53\fnil Symbol;}{\f54\fnil Wingdings;}{\f55\fnil Wingdings 2;}{\f56\fnil Wingdings 3;}{\f57\fnil Webdings;}{\f58\fnil Arial Narrow;}{\f59\fnil Arial Unicode MS;}{\f60\fnil Cyberbit;}{\f61\fnil Morningstar 1U Light;}{\f62\fnil Calibri;}}
{\colortbl;\red0\green0\blue0;\red127\green0\blue0;\red0\green0\blue255;\red127\green127\blue127;\red0\green51\blue153;\red255\green204\blue0;\red255\green255\blue255;\red246\green244\blue236;\red0\green0\blue0;\red1\green1\blue1;\red204\green238\blue255;}
{\*\bkmkstart filing_1}{\*\bkmkend filing_1}{\*\bkmkstart doc_1_1}{\*\bkmkend doc_1_1}\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\cf1\f51\fs2\ql \~\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs36\b\qc UNITED STATES\par\pard\plain\cf1\f51\fs36\b\qc SECURITIES AND EXCHANGE COMMISSION\par\pard\plain\cf1\f51\fs20\b\qc WASHINGTON, D.C. 20549\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs36\b\qc FORM\~10-Q\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f54\fs24\b\ql x\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\plain\li550\cf1\f51\fs24\b\ql QUARTERLY REPORT PURSUANT TO SECTION\~13 OR 15(d)\~OF THE SECURITIES\plain\li550\cf1\f51\fs24\b\ql EXCHANGE ACT OF 1934\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc For the quarterly period ended June\~30, 2017\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc OR\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f54\fs24\b\ql o\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs24\b\ql TRANSITION REPORT PURSUANT TO SECTION\~13 OR 15(d)\~OF THE SECURITIES\plain\li550\cf1\f51\fs24\b\ql EXCHANGE ACT OF 1934\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc For the transition period from \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~ to\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc Commission File Number: 001-37926\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\cf1\f51\fs20\ql \~\par\qc{\*\shppict{\pict\jpegblip\picw134\pich50\picscalex75\picscaley75\bliptag-9926104239
{\*\blipuid 161a7114a72c55967ff4fe2c0bb5df3e}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}}
\par\pard\plain\cf1\f51\fs20\qc \~\par\pard\plain\cf1\f51\fs36\b\qc RA PHARMACEUTICALS,\~INC.\par\pard\plain\cf1\f51\fs20\qc (Exact name of registrant as specified in its charter)\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\trqc\cellx5292\clvertalb\cellx5507\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\b\qc Delaware\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\b\qc 26-2908274\cell{
{\trowd\trqc\cellx5292\clvertalb\cellx5507\cellx10799\trrh248\row}}}
{\trowd\trqc\cellx5292\clvertalb\cellx5507\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\qc (State or other jurisdiction of\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qc (I.R.S. Employer\cell{
{\trowd\trqc\cellx5292\clvertalb\cellx5507\cellx10799\trrh248\row}}}
{\trowd\trqc\cellx5292\clvertalb\cellx5507\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\qc incorporation or organization)\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qc Identification No.)\cell{
{\trowd\trqc\cellx5292\clvertalb\cellx5507\cellx10799\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\cellx5292\clvertalb\cellx5507\clvertalb\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\b\qc 87 Cambridge Park Drive\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qc \~\cell{
{\trowd\cellx5292\clvertalb\cellx5507\clvertalb\cellx10799\trrh248\row}}}
{\trowd\cellx5292\clvertalb\cellx5507\clvertalb\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\b\qc Cambridge, MA\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\b\qc 02140\cell{
{\trowd\cellx5292\clvertalb\cellx5507\clvertalb\cellx10799\trrh248\row}}}
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\qc (Address of principal executive offices)\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qc (Zip code)\cell{
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc 617-401-4060\par\pard\plain\cf1\f51\fs20\qc (Registrant\u8217?s telephone number, including area code)\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Indicate by check mark whether the registrant (1)\~has filed all reports required to be filed by Section\~13 or 15(d)\~of the Securities\plain\cf1\f51\fs20\ql Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such\plain\cf1\f51\fs20\ql reports), and (2)\~has been subject to such filing requirements for the past 90 days.\~\~\~\~Yes\~\~\plain\cf1\f54\fs20\ql x\plain\cf1\f51\fs20\ql \~\~\~\~No\~\~\plain\cf1\f54\fs20\ql o\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every\plain\cf1\f51\fs20\ql Interactive Data File required to be submitted and posted pursuant to Rule\~405 of Regulation S-T during the preceding 12\plain\cf1\f51\fs20\ql months (or for such shorter period that the registrant was required to submit and post such files).\~\~\~\~Yes\~\~\plain\cf1\f54\fs20\ql x\plain\cf1\f51\fs20\ql \~\~\~\~No\~\~\plain\cf1\f54\fs20\ql o\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller\plain\cf1\f51\fs20\ql reporting company, or an emerging growth company. See definitions of \u8220?accelerated filer,\u8221? \u8220?large accelerated\plain\cf1\f51\fs20\ql filer\u8221?, \u8220?smaller reporting company,\u8221? and \u8220?emerging growth company\u8221? in Rule\~12b-2 of the\plain\cf1\f51\fs20\ql Exchange Act. (Check one):\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\qc Large\~accelerated\~filer\plain\intbl\cf1\f54\fs20\qc o\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qc Accelerated\~filer\plain\intbl\cf1\f54\fs20\qc o\cell{
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248\row}}}
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\qc \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qc \~\cell{
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248\row}}}
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\qc Non-accelerated filer\plain\intbl\cf1\f54\fs20\qc x\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qc Smaller\~reporting\~company\plain\intbl\cf1\f54\fs20\qc o\cell{
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248\row}}}
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\qc (Do not check if a smaller reporting company)\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qc \~\cell{
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248\row}}}
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\qc \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248\row}}}
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\qc Emerging growth company\plain\intbl\cf1\f54\fs20\qc x\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5292\clvertalb\cellx5507\cellx10799\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for\plain\cf1\f51\fs20\ql complying with any new or revised financial accounting standards provided pursuant to Section\~13(a)\~of the Exchange Act.\~\~\~\~\plain\cf1\f54\fs20\ql x\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Indicate by check mark whether the registrant is a shell company (as defined in Rule\~12b-2 of the Exchange\plain\cf1\f51\fs20\ql Act).\~\~\~\~Yes\~\~\plain\cf1\f54\fs20\ql o\plain\cf1\f51\fs20\ql \~\~\~\~No\~\~\plain\cf1\f54\fs20\ql x\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc The number of shares outstanding of the registrant\u8217?s common stock as of July\~31, 2017 was 22,609,646.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\brdrb\brdrs\cf1\f51\fs2\ql \~\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc NOTE REGARDING\~FORWARD-LOOKING\~STATEMENTS\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql This Quarterly Report on Form\~10-Q contains \u8220?forward-looking statements\u8221? within the meaning of\plain\cf1\f51\fs20\ql Section\~27A of the Securities Act of 1933, as amended (the \u8220?Securities Act\u8221?), and Section\~21E of the Securities\plain\cf1\f51\fs20\ql Exchange Act of 1934, as amended (the \u8220?Exchange Act\u8221?). We have based these forward-looking statements largely\plain\cf1\f51\fs20\ql on our current expectations and projections about future events and financial trends affecting the financial condition of our\plain\cf1\f51\fs20\ql business. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily\plain\cf1\f51\fs20\ql be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements\plain\cf1\f51\fs20\ql are based on information available at the time those statements are made and/or management\u8217?s good faith belief as of that\plain\cf1\f51\fs20\ql time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to\plain\cf1\f51\fs20\ql differ materially from those expressed in or suggested by the forward-looking statements.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Forward-looking statements include all statements that are not historical facts. In some cases, you can identify\plain\cf1\f51\fs20\ql forward-looking statements by terms such as \u8220?may,\u8221? \u8220?might,\u8221? \u8220?will,\u8221?\plain\cf1\f51\fs20\ql \u8220?objective,\u8221? \u8220?intend,\u8221? \u8220?should,\u8221? \u8220?could,\u8221? \u8220?can,\u8221?\plain\cf1\f51\fs20\ql \u8220?would,\u8221? \u8220?expect,\u8221? \u8220?believe,\u8221? \u8220?anticipate,\u8221? \u8220?project,\u8221?\plain\cf1\f51\fs20\ql \u8220?target,\u8221? \u8220?design,\u8221? \u8220?estimate,\u8221? \u8220?predict,\u8221? \u8220?potential,\u8221?\plain\cf1\f51\fs20\ql \u8220?plan\u8221? or the negative of these terms, and similar expressions intended to identify forward-looking statements, and\plain\cf1\f51\fs20\ql similar expressions and comparable terminology intended to identify forward -looking statements. These statements reflect our\plain\cf1\f51\fs20\ql current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including those\plain\cf1\f51\fs20\ql set forth in Item\~1A, \u8220?Risk Factors\u8221? and elsewhere in our Annual Report on Form\~10-K for the year ended\plain\cf1\f51\fs20\ql December\~31, 2016, as supplemented by our subsequent filings with the Securities and Exchange Commission (the\plain\cf1\f51\fs20\ql \u8220?SEC\u8221?). Forward-looking statements include, but are not limited to, statements about:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the initiation, timing, progress and results of our research and development programs and future preclinical and\plain\li1122\cf1\f51\fs20\ql clinical studies;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the risk that initial data from our ongoing Phase 2 clinical trial may not be indicative of final study results or data\plain\li1122\cf1\f51\fs20\ql from other patients that we obtain from this clinical trial;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql our ability to advance any product candidates into, and successfully complete, clinical studies and obtain\plain\li1122\cf1\f51\fs20\ql regulatory approval for them;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql our ability to identify additional product candidates using our Extreme Diversity\plain\li1122\cf1\f51\fs13\ql TM\plain\li1122\cf1\f51\fs20\ql \~platform;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the timing or likelihood of regulatory filings and approvals;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the commercialization, marketing and manufacturing of our product candidates, if approved;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the pricing and reimbursement of our product candidates, if approved;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the rate and degree of market acceptance and clinical utility of any products for which we receive marketing\plain\li1122\cf1\f51\fs20\ql approval;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the implementation of our strategic plans for our business, product candidates and technology;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the scope of protection we are able to establish and maintain for intellectual property rights covering our product\plain\li1122\cf1\f51\fs20\ql candidates and technology;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql our expectations related to the use of proceeds from our initial public offering, and estimates of our expenses,\plain\li1122\cf1\f51\fs20\ql future revenues, capital requirements and our needs for additional financing;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql our ability to maintain and establish collaborations;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql our financial performance;\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql developments relating to our competitors and our industry, including the impact of government regulation; and\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql other risks and uncertainties, including those listed under the caption \u8220?Risk Factors\u8221? in our Annual\plain\li1122\cf1\f51\fs20\ql Report on Form\~10-K for the year ended December\~31, 2016.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Given these uncertainties, you should not place undue reliance on these forward looking statements. These forward looking\plain\cf1\f51\fs20\ql statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form\~10-Q and, except as\plain\cf1\f51\fs20\ql required by law, we undertake no obligation to update or revise publicly any forward looking-statements, whether as a result of\plain\cf1\f51\fs20\ql new information, future events or otherwise after the date of this Quarterly Report on Form\~10-Q. We qualify all of our forward\plain\cf1\f51\fs20\ql looking statements by these cautionary statements.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc NOTE REGARDING TRADEMARKS\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql All brand names or trademarks appearing in this report are the property of their respective holders. Unless the context\plain\cf1\f51\fs20\ql requires otherwise, references in this report to the \u8220?Company,\u8221? \u8220?we,\u8221? \u8220?us,\u8221? and\plain\cf1\f51\fs20\ql \u8220?our\u8221? refer to Ra Pharmaceuticals,\~Inc.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc TABLE OF CONTENTS{\*\bkmkstart TableOfContents}{\*\bkmkend TableOfContents}\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx1188\clvertalb\cellx9720\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10800\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Page\cell{
{\trowd\clvertalb\cellx1188\clvertalb\cellx9720\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10800\trrh198\row}}}
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell{
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "PARTIFINANCIALINFORMATION_033124" }{\*\fldrslt\cf3\f51\fs20\b\ql PART\~I \u8212? FINANCIAL INFORMATION}}\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell{
{\trowd\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item1_FinancialStatements_033133" }{\*\fldrslt\cf3\f51\fs20\ql Item 1.}}\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item1_FinancialStatements_033133" }{\*\fldrslt\cf3\f51\fs20\ql Financial Statements (Unaudited)}}\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell{
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "CONDENSEDCONSOLIDATEDBALANCESHEE" }{\*\fldrslt\cf3\f51\fs20\ql Condensed Consolidated Balance Sheets as of June\~30, 2017 and December\~31, 2016}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 4\cell{
{\trowd\cellx1188\cellx9720\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\cellx10800\trrh495
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "CONDENSEDCONSOLIDATEDSTATEMENTSO" }{\*\fldrslt\cf3\f51\fs20\ql Condensed Consolidated Statements of Operations for the three and six months ended June\~30, 2017}}\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "CONDENSEDCONSOLIDATEDSTATEMENTSO" }{\*\fldrslt\cf3\f51\fs20\ql and 2016}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 5\cell{
{\trowd\cellx1188\cellx9720\cellx10800\trrh495\row}}}
{\trowd\cellx1188\cellx9720\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "CONDENSEDCONSOLIDATEDSTATEMENTSO" }{\*\fldrslt\cf3\f51\fs20\ql Condensed Consolidated Statements of Cash Flows for the six months ended June\~30, 2017 and 2016}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 6\cell{
{\trowd\cellx1188\cellx9720\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "NOTESTOUNAUDITEDCONDENSEDCONSOLI" }{\*\fldrslt\cf3\f51\fs20\ql Notes to Condensed Consolidated Financial Statements}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 7\cell{
{\trowd\cellx1188\cellx9720\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item2ManagementsDiscussionandAna" }{\*\fldrslt\cf3\f51\fs20\ql Item 2.}}\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item2ManagementsDiscussionandAna" }{\*\fldrslt\cf3\f51\fs20\ql Management\u8217?s Discussion and Analysis of Financial Condition and Results of Operations}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 13\cell{
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item3_QuantitativeandQualitative" }{\*\fldrslt\cf3\f51\fs20\ql Item 3.}}\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item3_QuantitativeandQualitative" }{\*\fldrslt\cf3\f51\fs20\ql Quantitative and Qualitative Disclosures About Market Risk}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 21\cell{
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item4_ControlsandProcedures_0402" }{\*\fldrslt\cf3\f51\fs20\ql Item 4.}}\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item4_ControlsandProcedures_0402" }{\*\fldrslt\cf3\f51\fs20\ql Controls and Procedures}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 21\cell{
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell{
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "PARTIIOTHERINFORMATION_040259" }{\*\fldrslt\cf3\f51\fs20\b\ql PART\~II \u8212? OTHER INFORMATION}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 22\cell{
{\trowd\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item1A_RiskFactors_040305" }{\*\fldrslt\cf3\f51\fs20\ql Item 1A.}}\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item1A_RiskFactors_040305" }{\*\fldrslt\cf3\f51\fs20\ql Risk Factors}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 22\cell{
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item2_UnregisteredSalesofEquityS" }{\*\fldrslt\cf3\f51\fs20\ql Item 2.}}\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item2_UnregisteredSalesofEquityS" }{\*\fldrslt\cf3\f51\fs20\ql Unregistered Sales of Equity Securities and Use of Proceeds}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 22\cell{
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item6_Exhibits_055350" }{\*\fldrslt\cf3\f51\fs20\ql Item 6.}}\cell\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "Item6_Exhibits_055350" }{\*\fldrslt\cf3\f51\fs20\ql Exhibits}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 23\cell{
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell{
{\trowd\cellx1188\cellx9720\clvertalb\cellx10800\trrh248\row}}}
{\trowd\cellx9720\clvertalb\cellx10800\trrh248
\pard\plain\intbl\ul{\field{\*\fldinst HYPERLINK \\l "SIGNATURES_040035" }{\*\fldrslt\cf3\f51\fs20\b\ql SIGNATURES}}\cell\pard\plain\intbl\cf1\f51\fs20\qr 24\cell{
{\trowd\cellx9720\clvertalb\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 3{\*\bkmkstart PB_3_152406_4411}{\*\bkmkend PB_3_152406_4411}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart part_1_2_1}{\*\bkmkend part_1_2_1}\par\pard\plain\cf1\f51\fs20\b\ql PART\~I: FINANCIAL INFORMATION{\*\bkmkstart PARTIFINANCIALINFORMATION_033124}{\*\bkmkend PARTIFINANCIALINFORMATION_033124}\par\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart item_1_3_1}{\*\bkmkend item_1_3_1}\par\pard\plain\li1078\fi-1078\cf1\f51\fs20\b\ql Item 1.\plain\li1078\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1078\cf1\f51\fs20\b\ql Financial Statements{\*\bkmkstart Item1_FinancialStatements_033133}{\*\bkmkend Item1_FinancialStatements_033133}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc RA PHARMACEUTICALS,\~INC.\par\pard\plain\cf1\f51\fs20\b\qc CONDENSED CONSOLIDATED BALANCE SHEETS{\*\bkmkstart CONDENSEDCONSOLIDATEDBALANCESHEE}{\*\bkmkend CONDENSEDCONSOLIDATEDBALANCESHEE}\par\pard\plain\cf1\f51\fs20\b\qc (UNAUDITED)\par\pard\plain\cf1\f51\fs20\b\qc (In thousands, except per share data)\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx6629\clvertalb\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8565\clvertalb\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc June\~30,\~2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc December\~31,\~2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx6629\clvertalb\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8565\clvertalb\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\b\ql Assets\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Current assets:\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7286\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8564\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8757\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9413\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10691\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Cash and cash equivalents\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 96,605\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 117,812\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7286\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8564\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8757\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9413\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10691\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8565\clvertalb\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Prepaid expenses and other current assets\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,231\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,690\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8565\clvertalb\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Total current assets\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 97,836\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 119,502\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Property and equipment, net\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 6,239\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 5,537\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Intangible assets, net\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 229\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 262\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Goodwill\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 183\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 183\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Restricted cash\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,334\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,334\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7286\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8564\clvertalb\cellx8757\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx9413\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx10691\clvertalb\cellx10795\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Total assets\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 105,821\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 126,818\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7286\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8564\clvertalb\cellx8757\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx9413\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx10691\clvertalb\cellx10795\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\b\ql Liabilities and Stockholders\u8217? Equity\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Current liabilities:\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7286\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8564\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8757\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9413\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10691\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Accounts payable\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,134\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,252\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7286\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8564\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8757\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9413\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10691\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Accrued expenses\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,444\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,182\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Deferred rent\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 422\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 303\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8565\clvertalb\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Total current liabilities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 7,000\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 6,737\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8565\clvertalb\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Deferred rent, net of current portion\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,586\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,800\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8565\clvertalb\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Deferred tax liabilities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 59\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 59\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8565\clvertalb\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Total liabilities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 9,645\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 9,596\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Commitments and contingencies\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Stockholders\u8217? equity:\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh495
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued\plain\intbl\li440\cf1\f51\fs20\ql and outstanding\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh495\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh743
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Common stock, $0.001 par value; 150,000 shares authorized; 22,597 and\plain\intbl\li440\cf1\f51\fs20\ql 22,546 shares issued and outstanding as of June\~30, 2017 and\plain\intbl\li440\cf1\f51\fs20\ql December\~31, 2016, respectively\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 23\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 23\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh743\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Additional paid-in capital\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 188,951\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 185,963\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clvertalb\cellx8565\clvertalb\cellx8758\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Accumulated deficit\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (92,798\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (68,764\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8565\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10797\trrh248\row}}}
{\trowd\cellx6629\clvertalb\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8565\clvertalb\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Total stockholders\u8217? equity\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 96,176\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 117,222\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6629\clvertalb\cellx6812\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8565\clvertalb\cellx8758\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7286\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8564\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8757\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9413\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10691\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Total liabilities and stockholders\u8217? equity\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 105,821\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 126,818\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6629\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6812\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7286\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8564\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8757\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9413\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10691\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc See Notes to Unaudited Condensed Consolidated Financial Statements.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 4{\*\bkmkstart PB_4_152646_4822}{\*\bkmkend PB_4_152646_4822}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc RA PHARMACEUTICALS,\~INC.\par\pard\plain\cf1\f51\fs20\b\qc CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS{\*\bkmkstart CONDENSEDCONSOLIDATEDSTATEMENTSO}{\*\bkmkend CONDENSEDCONSOLIDATEDSTATEMENTSO}\par\pard\plain\cf1\f51\fs20\b\qc (UNAUDITED)\par\pard\plain\cf1\f51\fs20\b\qc (in thousands, except per share data)\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx4135\clvertalb\cellx4312\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7471\clvertalb\cellx7652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10796\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Three\~Months\~Ended\~June\~30,\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Six\~Months\~Ended\~June\~30,\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx4135\clvertalb\cellx4312\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7471\clvertalb\cellx7652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10796\trrh198\row}}}
{\trowd\clvertalb\cellx4135\clvertalb\cellx4312\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5700\clvertalb\cellx6117\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7471\clvertalb\cellx7652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9000\clvertalb\cellx9378\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10795\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx4135\clvertalb\cellx4312\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5700\clvertalb\cellx6117\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7471\clvertalb\cellx7652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9000\clvertalb\cellx9378\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10795\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4729\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5699\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6116\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7470\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7651\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8029\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8999\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9377\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10692\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10794\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Revenue\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,044\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 4,928\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4729\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5699\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6116\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7470\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7651\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8029\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8999\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9377\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10692\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10794\trrh248\row}}}
{\trowd\cellx4135\clvertalb\cellx4312\clvertalb\cellx5700\clvertalb\cellx6117\clvertalb\cellx7471\clvertalb\cellx7652\clvertalb\cellx9000\clvertalb\cellx9378\clvertalb\cellx10693\clvertalb\cellx10795\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Operating expenses:\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx4135\clvertalb\cellx4312\clvertalb\cellx5700\clvertalb\cellx6117\clvertalb\cellx7471\clvertalb\cellx7652\clvertalb\cellx9000\clvertalb\cellx9378\clvertalb\cellx10693\clvertalb\cellx10795\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5700\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6117\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7652\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9000\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9378\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Research and development\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 10,464\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 6,505\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 19,476\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 11,462\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5700\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6117\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7652\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9000\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9378\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248\row}}}
{\trowd\cellx4135\clvertalb\cellx4312\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5700\clvertalb\cellx6117\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7471\clvertalb\cellx7652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9000\clvertalb\cellx9378\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10795\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql General and administrative\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,348\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,085\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 4,817\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,376\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx4135\clvertalb\cellx4312\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5700\clvertalb\cellx6117\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7471\clvertalb\cellx7652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9000\clvertalb\cellx9378\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10795\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5700\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6117\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7652\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9000\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9378\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Total operating expenses\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 12,812\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 7,590\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 24,293\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 13,838\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5700\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6117\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7652\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9000\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9378\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248\row}}}
{\trowd\cellx4135\clvertalb\cellx4312\clvertalb\cellx5700\clvertalb\cellx6117\clvertalb\cellx7471\clvertalb\cellx7652\clvertalb\cellx9000\clvertalb\cellx9378\clvertalb\cellx10693\clvertalb\cellx10795\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Loss from operations\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (12,812\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (4,546\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (24,293\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (8,910\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\cellx4135\clvertalb\cellx4312\clvertalb\cellx5700\clvertalb\cellx6117\clvertalb\cellx7471\clvertalb\cellx7652\clvertalb\cellx9000\clvertalb\cellx9378\clvertalb\cellx10693\clvertalb\cellx10795\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5700\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6117\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7652\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9000\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9378\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Other income (expense), net\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 149\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (260\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr 270\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (952\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5700\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6117\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7652\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9000\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9378\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248\row}}}
{\trowd\cellx4135\clvertalb\cellx4312\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4729\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5699\clvertalb\cellx6116\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6533\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7470\clvertalb\cellx7651\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8029\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8999\clvertalb\cellx9377\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx9755\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx10692\clvertalb\cellx10794\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Net loss\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (12,663\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (4,806\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (24,023\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (9,862\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\cellx4135\clvertalb\cellx4312\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4729\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5699\clvertalb\cellx6116\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6533\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7470\clvertalb\cellx7651\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8029\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8999\clvertalb\cellx9377\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx9755\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx10692\clvertalb\cellx10794\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5700\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6117\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7652\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9000\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9378\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5700\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6117\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7652\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9000\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9378\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10693\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10795\trrh248\row}}}
{\trowd\cellx4135\clvertalb\cellx4312\clvertalb\cellx5700\clvertalb\cellx6117\clvertalb\cellx7471\clvertalb\cellx7652\clvertalb\cellx9000\clvertalb\cellx9378\clvertalb\cellx10693\clvertalb\cellx10795\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\cellx4135\clvertalb\cellx4312\clvertalb\cellx5700\clvertalb\cellx6117\clvertalb\cellx7471\clvertalb\cellx7652\clvertalb\cellx9000\clvertalb\cellx9378\clvertalb\cellx10693\clvertalb\cellx10795\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4729\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5699\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6116\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7470\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7651\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8029\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8999\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9377\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10692\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10794\trrh495
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Net loss per common share \u8212? basic and\plain\intbl\li440\cf1\f51\fs20\ql diluted\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (0.56\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (8.90\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (1.06\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (18.32\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx4135\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4312\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4729\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5699\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6116\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6533\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7470\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7651\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8029\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8999\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9377\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9755\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10692\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10794\trrh495\row}}}
{\trowd\cellx4135\clvertalb\cellx4312\clvertalb\cellx5700\clvertalb\cellx6117\clvertalb\cellx7471\clvertalb\cellx7652\clvertalb\cellx9000\clvertalb\cellx9378\clvertalb\cellx10693\clvertalb\cellx10795\trrh495
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Weighted average number of common shares\plain\intbl\li440\cf1\f51\fs20\ql outstanding \u8212? basic and diluted\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 22,575\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 540\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 22,562\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 538\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx4135\clvertalb\cellx4312\clvertalb\cellx5700\clvertalb\cellx6117\clvertalb\cellx7471\clvertalb\cellx7652\clvertalb\cellx9000\clvertalb\cellx9378\clvertalb\cellx10693\clvertalb\cellx10795\trrh495\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc See Notes to Unaudited Condensed Consolidated Financial Statements.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 5{\*\bkmkstart PB_5_152851_5335}{\*\bkmkend PB_5_152851_5335}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc RA PHARMACEUTICALS,\~INC.\par\pard\plain\cf1\f51\fs20\b\qc CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS{\*\bkmkstart CONDENSEDCONSOLIDATEDSTATEMENTSO}{\*\bkmkend CONDENSEDCONSOLIDATEDSTATEMENTSO}\par\pard\plain\cf1\f51\fs20\b\qc (UNAUDITED)\par\pard\plain\cf1\f51\fs20\b\qc (in thousands)\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx7361\clvertalb\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10798\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Six\~Months\~Ended\~June\~30,\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx7361\clvertalb\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10798\trrh198\row}}}
{\trowd\clvertalb\cellx7361\clvertalb\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8940\clvertalb\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10798\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx7361\clvertalb\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8940\clvertalb\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10798\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\b\ql Cash flows from operating activities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx7931\clvertalb\cellx8939\clvertalb\cellx9317\clvertalb\cellx9695\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Net loss\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (24,023\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (9,862\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx7931\clvertalb\cellx8939\clvertalb\cellx9317\clvertalb\cellx9695\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Adjustments to reconcile net loss to net cash used in operating activities:\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Depreciation and amortization\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 730\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 669\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Stock-based compensation\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,250\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 271\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Change in fair value of preferred stock tranche rights\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 960\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Other, net\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 7\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 19\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Changes in operating assets and liabilities:\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Prepaid expenses and other current assets\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 313\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (419\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Non-current assets\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (27\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Accounts payable and accrued expenses\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (96\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,499\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Deferred rent\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (95\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,428\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Deferred revenue\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (1,862\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8940\clvertalb\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li880\fi-220\cf1\f51\fs20\ql Net cash used in operating activities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (20,914\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (5,324\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8940\clvertalb\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\b\ql Cash flows from investing activities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Purchase of property and equipment\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (1,128\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (3,221\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Other, net\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 133\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8940\clvertalb\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li880\fi-220\cf1\f51\fs20\ql Net cash used in investing activities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (1,128\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (3,088\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8940\clvertalb\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\b\ql Cash flows from financing activities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Proceeds from issuance of preferred stock, net of underwriter discounts\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 29,250\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Payment of preferred stock issuance costs\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (21\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Proceeds from disgorgement of stockholder\u8217?s short-swing profits\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 670\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Proceeds from exercises of stock options\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 165\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 43\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8940\clvertalb\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li880\fi-220\cf1\f51\fs20\ql Net cash provided by financing activities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 835\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 29,272\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8940\clvertalb\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Net increase (decrease) in cash and cash equivalents\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (21,207\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr 20,860\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clvertalb\cellx8940\clvertalb\cellx9318\clvertalb\cellx10694\clvertalb\cellx10798\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Cash and cash equivalents, beginning of period\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 117,812\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 19,386\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx7361\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7553\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9318\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10694\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10798\trrh248\row}}}
{\trowd\cellx7361\clvertalb\cellx7553\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7931\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8939\clvertalb\cellx9317\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx9695\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\b\ql Cash and cash equivalents, end of period\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 96,605\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 40,246\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx7361\clvertalb\cellx7553\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7931\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8939\clvertalb\cellx9317\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx9695\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx10693\clvertalb\cellx10797\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc See Notes to Unaudited Condensed Consolidated Financial Statements.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 6{\*\bkmkstart PB_6_153058_5796}{\*\bkmkend PB_6_153058_5796}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc RA PHARMACEUTICALS,\~INC.\par\pard\plain\cf1\f51\fs20\b\qc NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS{\*\bkmkstart NOTESTOUNAUDITEDCONDENSEDCONSOLI}{\*\bkmkend NOTESTOUNAUDITEDCONDENSEDCONSOLI}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\b\ql 1.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\b\ql Nature of Business and Basis of Presentation\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The accompanying condensed consolidated financial statements are unaudited and have been prepared by Ra\plain\cf1\f51\fs20\ql Pharmaceuticals,\~Inc. (the \u8220?Company\u8221?) in accordance with accounting principles generally accepted in the United\plain\cf1\f51\fs20\ql States (\u8220?U.S. GAAP\u8221?) and pursuant to the rules\~and regulations of the Securities and Exchange Commission. The\plain\cf1\f51\fs20\ql year-end condensed consolidated balance sheet data was derived from the Company\u8217?s audited financial statements, but\plain\cf1\f51\fs20\ql does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in\plain\cf1\f51\fs20\ql conjunction with the Company\u8217?s Annual Report on Form\~10-K for the year ended December\~31, 2016. The condensed\plain\cf1\f51\fs20\ql consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair\plain\cf1\f51\fs20\ql statement of the Company\u8217?s financial position and results of operations.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Description of Business\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The Company is a clinical-stage biopharmaceutical company using its proprietary peptide chemistry platform to create\plain\cf1\f51\fs20\ql novel therapeutics to treat life-threatening diseases that are caused by excessive or uncontrolled activation of the complement\plain\cf1\f51\fs20\ql system, an essential component of the body\u8217?s innate immune system. The Company\u8217?s lead product candidate,\plain\cf1\f51\fs20\ql RA101495, is being developed as a convenient self-administered subcutaneous (\u8220?SC\u8221?) injection, which is an\plain\cf1\f51\fs20\ql injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria (\u8220?PNH\u8221?), a rare,\plain\cf1\f51\fs20\ql chronic, life-threatening, blood disorder where red blood cells are mistakenly attacked and destroyed by the complement system.\plain\cf1\f51\fs20\ql The Company is also developing RA101495, administered SC, to treat other debilitating complement-mediated diseases such as\plain\cf1\f51\fs20\ql refractory generalized myasthenia gravis (\u8220?rMG\u8221?) and lupus nephritis (\u8220?LN\u8221?). The Company is also\plain\cf1\f51\fs20\ql pursuing discovery and preclinical programs targeting selective inhibition of other uncontrolled complement pathway factors to\plain\cf1\f51\fs20\ql treat a variety of ophthalmologic, renal and inflammatory diseases. In addition to its focus on developing novel therapeutics to\plain\cf1\f51\fs20\ql treat complement-mediated diseases, the Company has a collaboration with Merck\~&\~Co.,\~Inc. (\u8220?Merck\u8221?) for a\plain\cf1\f51\fs20\ql non-complement cardiovascular target.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The Company was incorporated in Delaware on June\~27, 2008 and is located in Cambridge, Massachusetts. During 2011,\plain\cf1\f51\fs20\ql the Company acquired Cosmix Verwaltungs\~GmbH (\u8220?Cosmix\u8221?), organized in Germany. In January\~2016, the\plain\cf1\f51\fs20\ql Company formed a wholly-owned subsidiary organized in the United Kingdom (\u8220?UK\u8221?), Ra Europe Limited, for the\plain\cf1\f51\fs20\ql purpose of conducting clinical trials in Europe and the UK.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Since inception, the Company has generated an accumulated deficit of $92.8 million as of June\~30, 2017 and has devoted\plain\cf1\f51\fs20\ql substantially all of its efforts to research and development, business planning, acquiring operating assets, seeking protection for its\plain\cf1\f51\fs20\ql technology and product candidates, and raising capital.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Initial Public Offering\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql On October\~31, 2016, the Company completed an initial public offering (\u8220?IPO\u8221?), in which the Company\plain\cf1\f51\fs20\ql issued and sold 7,049,230 shares of common stock (\u8220?Common Stock\u8221?) at a public offering price of $13.00 per\plain\cf1\f51\fs20\ql share, resulting in net proceeds of $82.8 million after deducting $6.4 million of underwriting discounts and commissions and\plain\cf1\f51\fs20\ql offering costs of $2.4 million. On November\~29, 2016, the Company completed the sale of an additional 1,057,385 shares of\plain\cf1\f51\fs20\ql Common Stock to the underwriters under the underwriters\u8217? option in the IPO to purchase additional shares at the public\plain\cf1\f51\fs20\ql offering price of $13.00 per share, resulting in net proceeds of $12.8 million after deducting underwriting discounts and\plain\cf1\f51\fs20\ql commissions of $1.0 million. The shares began trading on the NASDAQ Global Market on October\~26, 2016.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Use of Estimates\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company\plain\cf1\f51\fs20\ql make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related\plain\cf1\f51\fs20\ql disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and\plain\cf1\f51\fs20\ql methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to\plain\cf1\f51\fs20\ql be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual\plain\cf1\f51\fs20\ql results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported\plain\cf1\f51\fs20\ql results in the period in which they become known.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 7{\*\bkmkstart PB_7_152950_3969}{\*\bkmkend PB_7_152950_3969}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\b\i\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Consolidation\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The Company\u8217?s condensed consolidated financial statements reflect its financial statements and those of its\plain\cf1\f51\fs20\ql subsidiaries in which the Company holds a controlling financial interest, including Cosmix and Ra Europe Limited. Intercompany\plain\cf1\f51\fs20\ql balances and transactions are eliminated in consolidation.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Summary of Significant Accounting Policies\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The Company\u8217?s significant accounting policies are described in Note 2, \u8220?Summary of Significant Accounting\plain\cf1\f51\fs20\ql Policies,\u8221? in the Company\u8217?s Annual Report on Form\~10-K for the year ended December\~31, 2016.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Newly Adopted Accounting Pronouncements\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In March\~2016, the Financial Accounting Standards Board (\u8220?FASB\u8221?)\~ issued Accounting Standards Update\plain\cf1\f51\fs20\ql (\u8220?ASU\u8221?)\~ 2016-09, \u8220?\plain\cf1\f51\fs20\i\ql Improvements to Employee Share-Based Payment Accounting\plain\cf1\f51\fs20\ql .\u8221? The standard\plain\cf1\f51\fs20\ql reduces complexity in several aspects of the accounting for employee share-based compensation, including the income tax\plain\cf1\f51\fs20\ql consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The ASU is\plain\cf1\f51\fs20\ql effective for fiscal years beginning after December\~15, 2016, and interim periods within those fiscal years. The adoption of ASU\plain\cf1\f51\fs20\ql 2016-09 during the quarter ended March\~31, 2017 did not have a significant impact on the Company\u8217?s financial\plain\cf1\f51\fs20\ql statements and related disclosures. Upon adoption, the Company elected to account for forfeitures when they occur and recorded\plain\cf1\f51\fs20\ql a cumulative effect adjustment of $11,200 to accumulated deficit.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In November\~2015, the FASB issued ASU 2015-17, \u8220?\plain\cf1\f51\fs20\i\ql Balance Sheet Classification of Deferred Taxes\plain\cf1\f51\fs20\ql ,\u8221? that\plain\cf1\f51\fs20\ql requires companies to classify all deferred tax assets and liabilities, along with any valuation allowance, as noncurrent on the\plain\cf1\f51\fs20\ql balance sheet instead of separating deferred taxes into current and noncurrent amounts. The guidance does not change the existing\plain\cf1\f51\fs20\ql requirement that only permits offsetting within a jurisdiction. The ASU is effective for fiscal years beginning after December\~15,\plain\cf1\f51\fs20\ql 2016, and interim periods within those fiscal years. The adoption of ASU 2015-17 during the quarter ended March\~31, 2017 did\plain\cf1\f51\fs20\ql not have a significant impact on the Company\u8217?s financial statements and related disclosures.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Newly Issued Accounting Pronouncements\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In May\~2014, the FASB issued ASU\~ 2014-09, \u8220?\plain\cf1\f51\fs20\i\ql Revenue from Contracts with Customers\plain\cf1\f51\fs20\ql .\u8221? The standard,\plain\cf1\f51\fs20\ql including subsequently issued amendments, will replace most existing revenue recognition guidance in U.S. GAAP when it\plain\cf1\f51\fs20\ql becomes effective and permits the use of either the retrospective or cumulative effect transition method. The standard will require\plain\cf1\f51\fs20\ql an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to\plain\cf1\f51\fs20\ql customers. The standard will be effective for annual and interim periods beginning after December\~15, 2017. The Company has\plain\cf1\f51\fs20\ql not yet selected a transition method and is evaluating the impact the adoption will have on its consolidated financial statements\plain\cf1\f51\fs20\ql and related disclosures.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In February\~2016, the FASB issued ASU 2016-02, \u8220?\plain\cf1\f51\fs20\i\ql Leases\plain\cf1\f51\fs20\ql .\u8221? The standard established the principles that\plain\cf1\f51\fs20\ql lessees and lessors will apply to report useful information to users of financial statements about the amount, timing and\plain\cf1\f51\fs20\ql uncertainty of cash flows arising from a lease. The ASU is effective for fiscal years beginning after December\~15, 2018, and\plain\cf1\f51\fs20\ql interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the full impact this\plain\cf1\f51\fs20\ql standard will have on its consolidated financial statements and related disclosures, but expects to recognize substantially all of its\plain\cf1\f51\fs20\ql leases on the balance sheet by recording a right-to-use asset and a corresponding lease liability.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In August\~2016, the FASB issued ASU 2016-15, \u8220?\plain\cf1\f51\fs20\i\ql Classification of Certain Cash Receipts and Cash\plain\cf1\f51\fs20\i\ql Payments\plain\cf1\f51\fs20\ql .\u8221? The standard addresses the classification of certain transactions within the statement of cash flows, including\plain\cf1\f51\fs20\ql cash payments for debt prepayment or debt extinguishment costs, contingent consideration payments made after a business\plain\cf1\f51\fs20\ql combination, and distributions received from equity method investments. The ASU is effective for fiscal years beginning after\plain\cf1\f51\fs20\ql December\~15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is\plain\cf1\f51\fs20\ql not expected to have a material impact on the consolidated financial statements and related disclosures.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In November\~2016, the FASB issued ASU 2016-18, \u8220?\plain\cf1\f51\fs20\i\ql Restricted Cash\plain\cf1\f51\fs20\ql .\u8221? The standard addresses the\plain\cf1\f51\fs20\ql classification and presentation of restricted cash and restricted cash equivalents within the statement of cash flows. The ASU is\plain\cf1\f51\fs20\ql effective for fiscal years beginning after December\~15, 2017, and interim periods within those fiscal years. Early adoption is\plain\cf1\f51\fs20\ql permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related\plain\cf1\f51\fs20\ql disclosures.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In January\~2017, the FASB issued ASU 2017-04, \u8220?\plain\cf1\f51\fs20\i\ql Simplifying the Test for Goodwill Impairment\plain\cf1\f51\fs20\ql .\u8221? The\plain\cf1\f51\fs20\ql standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which requires a\plain\cf1\f51\fs20\ql hypothetical purchase price allocation. The ASU is effective for annual or interim goodwill impairment tests in fiscal years\plain\cf1\f51\fs20\ql beginning after December\~15, 2019, and should be applied on a prospective basis. Early adoption is permitted for interim or\plain\cf1\f51\fs20\ql annual goodwill impairment tests\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 8{\*\bkmkstart PB_8_153118_7056}{\*\bkmkend PB_8_153118_7056}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi44\cf1\f51\fs20\ql performed on testing dates after January\~1, 2017. The adoption of this standard is not expected to have a material impact on the\plain\cf1\f51\fs20\ql consolidated financial statements and related disclosures.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In May\~2017, the FASB issued ASU 2017-09, \u8220?\plain\cf1\f51\fs20\i\ql Scope of Modification Accounting\plain\cf1\f51\fs20\ql .\u8221? The standard \~clarifies\plain\cf1\f51\fs20\ql when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The ASU is\plain\cf1\f51\fs20\ql effective for fiscal years beginning after December\~15, 2017, and interim periods within those fiscal years. Early adoption is\plain\cf1\f51\fs20\ql permitted. The adoption of this standard is not expected to have a material impact on the consolidated financial statements and\plain\cf1\f51\fs20\ql related disclosures.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\b\ql 2.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\b\ql Supplemental Balance Sheet Information\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Property and equipment, net consists of the following (in thousands):\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx3914\clvertalb\cellx4105\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5736\clvertalb\cellx5940\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7794\clvertalb\cellx7880\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc June\~30,\~2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc December\~31,\~2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3914\clvertalb\cellx4105\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5736\clvertalb\cellx5940\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7794\clvertalb\cellx7880\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3914\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4105\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4579\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5736\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7793\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7879\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Computer equipment and software\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 20\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3914\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4105\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4579\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5736\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6596\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7793\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7879\trrh248\row}}}
{\trowd\cellx3914\clvertalb\cellx4105\clvertalb\cellx5736\clvertalb\cellx5940\clvertalb\cellx7794\clvertalb\cellx7880\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Furniture, fixtures, and other\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 378\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 365\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3914\clvertalb\cellx4105\clvertalb\cellx5736\clvertalb\cellx5940\clvertalb\cellx7794\clvertalb\cellx7880\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3914\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4105\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5736\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7880\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Laboratory equipment\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 4,667\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,642\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3914\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4105\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5736\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5940\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7880\trrh248\row}}}
{\trowd\cellx3914\clvertalb\cellx4105\clvertalb\cellx5736\clvertalb\cellx5940\clvertalb\cellx7794\clvertalb\cellx7880\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Construction in progress\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 328\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3914\clvertalb\cellx4105\clvertalb\cellx5736\clvertalb\cellx5940\clvertalb\cellx7794\clvertalb\cellx7880\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3914\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4105\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5736\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5940\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7880\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Leasehold improvements\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,744\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,732\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3914\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4105\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5736\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5940\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7880\trrh248\row}}}
{\trowd\cellx3914\clvertalb\cellx4105\clvertalb\cellx5736\clvertalb\cellx5940\clvertalb\cellx7794\clvertalb\cellx7880\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 9,137\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 7,739\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3914\clvertalb\cellx4105\clvertalb\cellx5736\clvertalb\cellx5940\clvertalb\cellx7794\clvertalb\cellx7880\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3914\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4105\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5736\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5940\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7880\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Accumulated depreciation\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (2,898\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (2,202\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3914\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4105\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5736\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5940\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7794\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7880\trrh248\row}}}
{\trowd\cellx3914\clvertalb\cellx4105\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4579\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5736\clvertalb\cellx5940\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6596\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7793\clvertalb\cellx7879\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Property and equipment, net\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 6,239\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 5,537\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3914\clvertalb\cellx4105\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4579\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5736\clvertalb\cellx5940\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6596\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7793\clvertalb\cellx7879\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\cf1\f51\fs20\ql Depreciation expense was $0.4 million and $0.3 million for the three months ended June\~30, 2017 and 2016 and $0.7\plain\li550\cf1\f51\fs20\ql million and $0.6 million for the six months ended June\~30, 2017 and 2016, respectively.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Accrued expenses consist of the following (in thousands):\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx3959\clvertalb\cellx4149\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5776\clvertalb\cellx5966\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7814\clvertalb\cellx7881\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc June\~30,\~2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc December\~31,\~2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3959\clvertalb\cellx4149\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5776\clvertalb\cellx5966\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7814\clvertalb\cellx7881\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3959\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4149\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4623\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5775\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5965\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6621\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7813\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7880\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Payroll and employee-related costs\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,194\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,451\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3959\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4149\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4623\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5775\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5965\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6621\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7813\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7880\trrh248\row}}}
{\trowd\cellx3959\clvertalb\cellx4149\clvertalb\cellx5776\clvertalb\cellx5966\clvertalb\cellx7814\clvertalb\cellx7881\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Research and development costs\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,768\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,326\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3959\clvertalb\cellx4149\clvertalb\cellx5776\clvertalb\cellx5966\clvertalb\cellx7814\clvertalb\cellx7881\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3959\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4149\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5776\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5966\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7814\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7881\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Other\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 482\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 405\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3959\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4149\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5776\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5966\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7814\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7881\trrh248\row}}}
{\trowd\cellx3959\clvertalb\cellx4149\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4623\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5775\clvertalb\cellx5965\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6621\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7813\clvertalb\cellx7880\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Total\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,444\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,182\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3959\clvertalb\cellx4149\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4623\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5775\clvertalb\cellx5965\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6621\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7813\clvertalb\cellx7880\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\b\ql 3.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\b\ql Fair Value Measurements\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The Company has certain assets recorded at fair value, which may be classified as Level 1, 2, or 3 within the fair value\plain\cf1\f51\fs20\ql hierarchy:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or\plain\li1122\cf1\f51\fs20\ql liabilities that the Company has the ability to access.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in\plain\li1122\cf1\f51\fs20\ql active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and\plain\li1122\cf1\f51\fs20\ql unobservable.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The fair value hierarchy level is determined by asset and liability class based on the lowest level of significant input. The\plain\cf1\f51\fs20\ql observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be\plain\cf1\f51\fs20\ql reclassified between levels. The Company recognizes\~transfers\~between levels within the fair value hierarchy, if any, at the\~end\~of\plain\cf1\f51\fs20\ql each quarter. During the three and six months ended June\~30, 2017, there were no transfers between levels.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Valuation methodologies used for assets measured or disclosed at fair value are as follows:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li1122\fi-550\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql Cash equivalents - Valued at market prices determined through third-party pricing services.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 9{\*\bkmkstart PB_9_153433_5335}{\*\bkmkend PB_9_153433_5335}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Assets measured at fair value on a recurring basis are summarized below (in thousands):\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx3168\clvertalb\cellx3344\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9196\clvertalb\cellx9285\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc June\~30,\~2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3168\clvertalb\cellx3344\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9196\clvertalb\cellx9285\trrh198\row}}}
{\trowd\clvertalb\cellx3168\clvertalb\cellx3344\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4685\clvertalb\cellx4865\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6211\clvertalb\cellx6391\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7737\clvertalb\cellx7917\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9194\clvertalb\cellx9283\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Level\~1\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Level\~2\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Level\~3\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Total\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3168\clvertalb\cellx3344\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4685\clvertalb\cellx4865\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6211\clvertalb\cellx6391\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7737\clvertalb\cellx7917\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9194\clvertalb\cellx9283\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3168\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3344\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3600\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4684\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4864\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5120\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6210\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6390\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6646\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7736\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7916\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9192\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9281\trrh495
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Cash equivalents \u8212? Money\plain\intbl\li220\cf1\f51\fs20\ql market funds\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 97,147\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 97,147\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3168\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3344\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3600\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4684\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4864\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5120\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6210\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6390\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6646\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7736\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7916\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8108\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9192\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9281\trrh495\row}}}
{\trowd\cellx3168\clvertalb\cellx3344\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx3600\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4684\clvertalb\cellx4864\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5120\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6210\clvertalb\cellx6390\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6646\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7736\clvertalb\cellx7916\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8108\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx9192\clvertalb\cellx9281\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Total assets measured at fair value\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 97,147\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 97,147\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3168\clvertalb\cellx3344\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx3600\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4684\clvertalb\cellx4864\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5120\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6210\clvertalb\cellx6390\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6646\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7736\clvertalb\cellx7916\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8108\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx9192\clvertalb\cellx9281\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx3161\clvertalb\cellx3337\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9198\clvertalb\cellx9286\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc December\~31,\~2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3161\clvertalb\cellx3337\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9198\clvertalb\cellx9286\trrh198\row}}}
{\trowd\clvertalb\cellx3161\clvertalb\cellx3337\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4682\clvertalb\cellx4863\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6207\clvertalb\cellx6388\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7732\clvertalb\cellx7913\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9193\clvertalb\cellx9281\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Level\~1\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Level\~2\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Level\~3\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Total\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3161\clvertalb\cellx3337\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4682\clvertalb\cellx4863\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6207\clvertalb\cellx6388\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7732\clvertalb\cellx7913\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9193\clvertalb\cellx9281\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3161\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3337\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3593\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4681\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4862\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5118\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6206\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6387\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6643\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7731\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7912\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8104\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9192\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9280\trrh495
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Cash equivalents \u8212? Money\plain\intbl\li220\cf1\f51\fs20\ql market funds\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 117,708\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 117,708\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3161\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3337\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3593\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4681\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4862\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5118\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6206\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6387\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6643\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7731\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7912\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8104\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9192\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9280\trrh495\row}}}
{\trowd\cellx3161\clvertalb\cellx3337\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx3593\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4681\clvertalb\cellx4862\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5118\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6206\clvertalb\cellx6387\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6643\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7731\clvertalb\cellx7912\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8104\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx9192\clvertalb\cellx9280\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Total assets measured at fair value\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 117,708\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 117,708\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3161\clvertalb\cellx3337\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx3593\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4681\clvertalb\cellx4862\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5118\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6206\clvertalb\cellx6387\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6643\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7731\clvertalb\cellx7912\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8104\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx9192\clvertalb\cellx9280\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\b\ql 4.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\b\ql Redeemable Convertible Preferred Stock\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Series\~A Preferred Stock\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In February\~2010, the Company issued 12,887,999\~shares of Series\~A Preferred Stock pursuant to the Series\~A Preferred\plain\cf1\f51\fs20\ql Stock agreement at a price of $0.80176 per share. Additionally, investors were granted the right to purchase up to an additional\plain\cf1\f51\fs20\ql 21,552,566\~shares of the Company\u8217?s Series\~A Preferred Stock at a price of $0.80176 per share, in two subsequent closings\plain\cf1\f51\fs20\ql upon the Company meeting certain milestone criteria. In February\~2012 and March\~2014, the Board of Directors waived certain\plain\cf1\f51\fs20\ql milestone events provided for in the Series\~A Preferred Stock agreement and the Company issued 10,776,283\~and\plain\cf1\f51\fs20\ql 10,776,283\~shares, respectively, of Series\~A Preferred Stock at a price of $0.80176 per share. In October\~2016, upon the closing\plain\cf1\f51\fs20\ql of the Company\u8217?s IPO, all outstanding shares of Series\~A Preferred Stock converted into 4,920,074 shares of the\plain\cf1\f51\fs20\ql Company\u8217?s common stock.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Series\~B Preferred Stock\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In July\~2015, the Company issued 31,564,630\~shares of Series\~B-1 Preferred Stock pursuant to the Series\~B Preferred Stock\plain\cf1\f51\fs20\ql agreement at a price of $0.92667 per share. Additionally, investors were granted the right to purchase up to an additional\plain\cf1\f51\fs20\ql 29,362,452\~shares of the Company\u8217?s Series\~B-2 Preferred Stock\~ at a price of $0.99617, in any number of subsequent\plain\cf1\f51\fs20\ql closings upon the request of each investor or in a mandatory closing upon the Company meeting certain milestone criteria. In\plain\cf1\f51\fs20\ql June\~2016, the Board of Directors and required certain investors waived certain milestone events provided for in the Series\~B\plain\cf1\f51\fs20\ql Preferred Stock agreement\~ and the Company issued 29,362,452 shares of Series\~B-2 Preferred Stock at a price of $0.99617 per\plain\cf1\f51\fs20\ql share. In October\~2016, upon the closing of the Company\u8217?s IPO, all outstanding shares of Series\~B-1 and B-2 Preferred\plain\cf1\f51\fs20\ql Stock converted into 8,703,859 shares of the Company\u8217?s common stock.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Series\~A and Series\~B-2 Preferred Stock Tranche Rights\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The Company determined the rights of the investors to purchase additional shares of Series\~A and Series\~B-2 Preferred\plain\cf1\f51\fs20\ql Stock met the definition of a freestanding financial instrument and were recognized as a liability at fair value upon the initial\plain\cf1\f51\fs20\ql issuance of Series\~A and Series\~B-1 Preferred Stock in February\~2010 and July\~2015, respectively. The Company adjusted the\plain\cf1\f51\fs20\ql carrying value of the Series\~A and Series\~B-2 Preferred Stock Tranche Rights liability to its estimated fair value at each\plain\cf1\f51\fs20\ql subsequent reporting date and immediately prior to the subsequent issuances through charges to other income (expense), net in\plain\cf1\f51\fs20\ql the condensed consolidated statement of operations. The Series\~A Preferred Stock Tranche Rights liability was extinguished in\plain\cf1\f51\fs20\ql March\~2014 and the Series\~B-2 Preferred Stock Tranche Rights liability was extinguished in June\~2016. During the three and six\plain\cf1\f51\fs20\ql months ended June\~30, 2016, the Company adjusted the Series\~B-2 Preferred Stock Tranche Rights liability to its fair value and\plain\cf1\f51\fs20\ql recorded a charge of $0.2 million and $1.0 million, respectively.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\b\ql 5.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\b\ql Revenue Recognition\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In April\~2013, the Company entered into a multi-target collaboration and license agreement with Merck (\u8220?Merck\plain\cf1\f51\fs20\ql Agreement\u8221?) to use its proprietary drug discovery technology platform to identify orally available cyclic peptides for\plain\cf1\f51\fs20\ql non-complement program targets nominated by Merck and provide specific research and development services. Under the\plain\cf1\f51\fs20\ql agreement, the Company granted Merck licenses under certain of its intellectual property rights to manufacture, develop and\plain\cf1\f51\fs20\ql commercialize compounds and products directed to selected program targets. The agreement consists of a research phase, where\plain\cf1\f51\fs20\ql the Company and Merck collaborated on identifying and pre-clinically developing orally available cyclic peptides suitable for\plain\cf1\f51\fs20\ql further development by Merck, and a development and commercialization phase pursuant to which Merck has sole discretion and\plain\cf1\f51\fs20\ql responsibility, including financial responsibility, for further development and commercialization of these peptides, on a\plain\cf1\f51\fs20\ql program-by-program basis, from the collaboration. The research term ended in April\~2016.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 10{\*\bkmkstart PB_10_153616_5796}{\*\bkmkend PB_10_153616_5796}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql At the signing of the Merck Agreement, Merck made an upfront non-refundable, technology license fee of $4.5 million. In\plain\cf1\f51\fs20\ql addition, the Merck Agreement provides for reimbursement of research and development services provided by the Company and\plain\cf1\f51\fs20\ql includes milestone payments that could total up to $65.0 million.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The Company has identified two deliverables in connection with the Merck Agreement: (1)\~rights to access the\plain\cf1\f51\fs20\ql Company\u8217?s technology platform for each program target, and (2)\~the research\~and development services provided during\plain\cf1\f51\fs20\ql the research term. The Company has determined that none of the deliverables have standalone value. Since the separability\plain\cf1\f51\fs20\ql criteria have not been met for any of the deliverables, the deliverables were accounted for as a single combined unit of\plain\cf1\f51\fs20\ql accounting. The Company has recognized revenue in connection with the upfront non-refundable license fee ratably over the\plain\cf1\f51\fs20\ql research term. Payments for research and development services and reimbursement for certain lab supplies and reagents have\plain\cf1\f51\fs20\ql been recognized as services are performed.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The Company has determined that the $3.5\~million in milestone payments received was substantive in nature as they were\plain\cf1\f51\fs20\ql commensurate with the enhancement of value resulting from the Company\u8217?s performance under the Merck Agreement,\plain\cf1\f51\fs20\ql related solely to past performance and were reasonable relative to all of the deliverables and payment terms within the\plain\cf1\f51\fs20\ql arrangement. Accordingly, the Company has accounted for these milestone payments under the milestone method. The Company\plain\cf1\f51\fs20\ql is entitled to receive future aggregate milestone payments of up to $61.5\~million for the non-complement cardiovascular target\plain\cf1\f51\fs20\ql selected, consisting of remaining preclinical and clinical milestones of $16.5\~million, regulatory milestones of $19.0\~million, and\plain\cf1\f51\fs20\ql commercial milestones of $26.0\~million, and low-to-mid single digit percentage royalties on future sales, if any. Following the\plain\cf1\f51\fs20\ql end of the research term, any future milestone payments will be recognized as revenue upon achievement, assuming all other\plain\cf1\f51\fs20\ql revenue recognition criteria are met, as no further performance obligations exist for the Company under the Merck Agreement.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql During the three and six months ended June\~30, 2016, the Company recognized revenue of $3.0 million and $4.2 million\plain\cf1\f51\fs20\ql related to upfront, non-refundable payments, respectively. For the three and six months ended June\~30, 2016, the Company\plain\cf1\f51\fs20\ql recognized less than $0.1 million and $0.7 million related to research and development services and reimbursable expenses,\plain\cf1\f51\fs20\ql respectively. No revenue was recognized during the six months ended June\~30, 2017.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\b\ql 6.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\b\ql Stock-Based Compensation\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql The Company has stock-based compensation plans under which employees, directors and non-employees may be granted\plain\cf1\f51\fs20\ql stock-based awards such as stock options, stock appreciation rights, restricted stock awards, unrestricted stock awards, restricted\plain\cf1\f51\fs20\ql stock units, performance based awards or dividend equivalent rights.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql The following table provides stock-based compensation by the financial statement line item in which it is reflected (in\plain\cf1\f51\fs20\ql thousands):\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx3462\clvertalb\cellx3625\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6803\clvertalb\cellx6966\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10018\clvertalb\cellx10043\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Three\~Months\~Ended\~June\~30,\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Six\~Months\~Ended\~June\~30,\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3462\clvertalb\cellx3625\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6803\clvertalb\cellx6966\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10018\clvertalb\cellx10043\trrh198\row}}}
{\trowd\clvertalb\cellx3462\clvertalb\cellx3625\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5011\clvertalb\cellx5428\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6802\clvertalb\cellx6965\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8311\clvertalb\cellx8689\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10016\clvertalb\cellx10041\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3462\clvertalb\cellx3625\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5011\clvertalb\cellx5428\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6802\clvertalb\cellx6965\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8311\clvertalb\cellx8689\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10016\clvertalb\cellx10041\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3462\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3625\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4042\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5427\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5844\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6801\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6964\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7342\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8310\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8688\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9066\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10014\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10039\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Research and development\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 725\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 69\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,366\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 161\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3462\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3625\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4042\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5427\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5844\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6801\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6964\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7342\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8310\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8688\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9066\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10014\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10039\trrh248\row}}}
{\trowd\cellx3462\clvertalb\cellx3625\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5011\clvertalb\cellx5428\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6802\clvertalb\cellx6965\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8311\clvertalb\cellx8689\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10016\clvertalb\cellx10041\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql General and administrative\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 507\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 77\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 884\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 110\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3462\clvertalb\cellx3625\clbrdrb\brdrs\brdrcf1\clvertalb\cellx5011\clvertalb\cellx5428\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6802\clvertalb\cellx6965\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8311\clvertalb\cellx8689\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10016\clvertalb\cellx10041\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3462\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3625\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4042\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5427\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5844\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6801\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6964\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7342\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8310\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8688\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9066\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10014\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10039\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Total\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,232\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 146\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,250\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 271\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3462\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3625\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4042\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5427\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5844\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6801\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6964\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7342\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8310\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8688\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9066\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10014\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10039\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql During the six months ended June\~30, 2017, the Company issued 1.3 million stock options with a per share weighted average\plain\cf1\f51\fs20\ql grant date fair value of $11.90.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\b\ql 7.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\b\ql Net Loss Per Share\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The Company computes basic and diluted earnings (loss) per share using a methodology that gives effect to the impact of\plain\cf1\f51\fs20\ql outstanding participating securities (the \u8220?two-class method\u8221?). As the three and six months ended June\~30, 2017 and\plain\cf1\f51\fs20\ql 2016 resulted in net losses, there is no income allocation required under the two-class method or dilution attributed to weighted\plain\cf1\f51\fs20\ql average shares outstanding in the calculation of diluted loss per share.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 11{\*\bkmkstart PB_11_154016_2897}{\*\bkmkend PB_11_154016_2897}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The following Common Stock equivalents, presented on an as converted basis, were excluded from the computation of\plain\cf1\f51\fs20\ql diluted weighted average shares outstanding as their effect would be anti-dilutive (in thousands):\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx5476\clvertalb\cellx5720\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8555\clvertalb\cellx8637\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc As\~of\~June\~30,\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx5476\clvertalb\cellx5720\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8555\clvertalb\cellx8637\trrh198\row}}}
{\trowd\clvertalb\cellx5476\clvertalb\cellx5720\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6977\clvertalb\cellx7303\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8554\clvertalb\cellx8636\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx5476\clvertalb\cellx5720\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6977\clvertalb\cellx7303\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8554\clvertalb\cellx8636\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx5476\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5720\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6977\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7303\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8554\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8636\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Convertible preferred stock\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 13,624\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx5476\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5720\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6977\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7303\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8554\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8636\trrh248\row}}}
{\trowd\cellx5476\clvertalb\cellx5720\clvertalb\cellx6977\clvertalb\cellx7303\clvertalb\cellx8554\clvertalb\cellx8636\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Common stock warrants\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 223\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5476\clvertalb\cellx5720\clvertalb\cellx6977\clvertalb\cellx7303\clvertalb\cellx8554\clvertalb\cellx8636\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx5476\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5720\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6977\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7303\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8554\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8636\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Stock options\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,182\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,395\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx5476\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5720\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6977\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7303\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8554\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8636\trrh248\row}}}
{\trowd\cellx5476\clvertalb\cellx5720\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6977\clvertalb\cellx7303\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8554\clvertalb\cellx8636\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Total\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,182\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 15,242\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5476\clvertalb\cellx5720\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6977\clvertalb\cellx7303\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx8554\clvertalb\cellx8636\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql On April\~1, 2015, the Company entered into a Convertible Note Purchase Agreement with the holders of Series\~A Preferred\plain\cf1\f51\fs20\ql Stock and issued Convertible Notes and warrants to purchase 222,775 shares of the Company\u8217?s Common Stock. In\plain\cf1\f51\fs20\ql October\~2016, upon the closing of the IPO, all of the outstanding warrants net exercised, in accordance with their terms, into\plain\cf1\f51\fs20\ql 221,573 shares of Common Stock.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 12{\*\bkmkstart PB_12_154300_3020}{\*\bkmkend PB_12_154300_3020}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart item_1_3_2}{\*\bkmkend item_1_3_2}\par\pard\plain\cf1\f51\fs20\b\ql Item 2: Management\u8217?s Discussion and Analysis of Financial Condition and Results of Operations{\*\bkmkstart Item2ManagementsDiscussionandAna}{\*\bkmkend Item2ManagementsDiscussionandAna}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The following discussion should be read in conjunction with our condensed consolidated financial statements and\plain\cf1\f51\fs20\ql accompanying footnotes appearing elsewhere in this Quarterly Report on Form\~10-Q and our audited consolidated financial\plain\cf1\f51\fs20\ql statements and related footnotes included in our Annual Report on Form\~10-K for the year ended December\~31, 2016. Some of\plain\cf1\f51\fs20\ql the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form\~10-Q, including\plain\cf1\f51\fs20\ql information with respect to our plans and strategy for our business and related financing, includes forward-looking statements\plain\cf1\f51\fs20\ql that involve risks and uncertainties. Actual results may differ significantly from those projected in the forward-looking\plain\cf1\f51\fs20\ql statements. Factors that might cause future results to differ materially from those projected in the forward-looking statements\plain\cf1\f51\fs20\ql include, but are not limited to, those set forth in Item\~1A, \u8220?Risk Factors\u8221? and elsewhere in our Annual Report on\plain\cf1\f51\fs20\ql Form\~10-K for the year ended December\~31, 2016, as supplemented by our subsequent filings with the SEC.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li286\cf1\f51\fs20\b\ql Overview\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We are a clinical-stage biopharmaceutical company using our proprietary peptide chemistry platform to develop novel\plain\cf1\f51\fs20\ql therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement\plain\cf1\f51\fs20\ql system, a critical component of the immune system. The complement system, which consists of approximately 30 interacting\plain\cf1\f51\fs20\ql proteins, offers a target-rich opportunity for us to leverage our proprietary peptide chemistry platform, which was pioneered by\plain\cf1\f51\fs20\ql Nobel Laureate Dr.\~Jack Szostak and allows us to inhibit certain uncontrolled complement pathway factors involved in\plain\cf1\f51\fs20\ql complement-mediated diseases. Known as our Extreme Diversity platform, our proprietary macrocyclic peptide chemistry\plain\cf1\f51\fs20\ql technology allows us to produce synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the\plain\cf1\f51\fs20\ql pharmacological properties of small molecules. We believe this chemistry technology will allow us to pursue challenging targets\plain\cf1\f51\fs20\ql for which only monoclonal antibodies have been developed.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We are developing our lead product candidate, RA101495, a convenient self-administered subcutaneous\plain\cf1\f51\fs20\ql (\u8220?SC\u8221?) injection, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal\plain\cf1\f51\fs20\ql hemoglobinuria, or PNH. PNH is a rare, chronic, life-threatening, blood disorder where red blood cells are mistakenly attacked\plain\cf1\f51\fs20\ql and destroyed by the complement system. We initiated our Phase 2 clinical program for RA101495 in PNH patients in the\plain\cf1\f51\fs20\ql second quarter of 2017.\plain\cf1\f51\fs16\ql The global, dose-finding, twelve-week open label Phase 2 program is designed to evaluate the safety, tolerability,\plain\cf1\f51\fs16\ql preliminary efficacy, pharmacokinetics and pharmacodynamics of RA101495 in patients with PNH.\~ The study evaluates RA101495 in three cohorts.\~\plain\cf1\f51\fs16\ql Cohort A includes eculizumab-na\u239?ve patients, Cohort B includes patients switching from eculizumab to RA101495 and the third cohort includes\plain\cf1\f51\fs16\ql patients who are currently treated with eculizumab, but have evidence of an inadequate response.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In June\~2017, we released initial data from the Phase 2 program on two eculizumab-na\u239?ve patients treated with\plain\cf1\f51\fs20\ql RA101495 with seven weeks of follow-up.\~ Data showed no safety or tolerability concerns, no injection site reactions,\plain\cf1\f51\fs20\ql near-complete inhibition of hemolytic activity, rapid declines in lactate dehydrogenase (\u8220?LDH\u8221?) and 100%\plain\cf1\f51\fs20\ql compliance with the once daily, subcutaneous self-administration dosing regimen.\plain\cf1\f51\fs16\ql Based on these initial data, we commenced enrollment\plain\cf1\f51\fs16\ql in Cohort B, comprised of patients switching from eculizumab to RA101495. To date, seventeen patients have been enrolled in the Phase 2 program,\plain\cf1\f51\fs16\ql including nine patients in Cohort A representing an expanded range of elevated baseline LDH levels, and eight patients in Cohort B, with well-controlled\plain\cf1\f51\fs16\ql baseline LDH levels. A total of fourteen patients have received RA101495, eight patients in Cohort A and six patients in Cohort B. The first two patients\plain\cf1\f51\fs16\ql in Cohort A successfully completed the Phase 2 study and have elected to continue treatment with RA101495 in a long-term extension study. We expect\plain\cf1\f51\fs16\ql to report additional top-line data from our Phase 2 program around year-end 2017.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We are also developing RA101495, administered SC, to treat other debilitating complement-mediated diseases such as\plain\cf1\f51\fs20\ql refractory generalized myasthenia gravis (\u8220?rMG\u8221?) and lupus nephritis (\u8220?LN\u8221?). We expect to initiate a\plain\cf1\f51\fs20\ql Phase 2 clinical trial with RA101495 for rMG and a Phase 1b clinical trial supporting development in LN in the second half of\plain\cf1\f51\fs20\ql 2017. We also have preclinical programs targeting selective inhibition of other complement factors for diseases with no approved\plain\cf1\f51\fs20\ql therapies, including a Factor D program for ophthalmologic and renal diseases, an oral, small molecule C5 inhibitor and a C1\plain\cf1\f51\fs20\ql program for certain autoimmune and central nervous system (\u8220?CNS\u8221?) diseases. In addition to our focus on\plain\cf1\f51\fs20\ql developing novel therapeutics to treat complement-mediated diseases, we have validated our Extreme Diversity platform by\plain\cf1\f51\fs20\ql successfully identifying and delivering orally-available cyclic peptides for a non-complement cardiovascular target with a large\plain\cf1\f51\fs20\ql market opportunity in a collaboration with Merck\~& Co.,\~Inc. (\u8220?Merck\u8221?).\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Since our inception in June\~2008, we have devoted substantially all of our resources to organizing and staffing our\plain\cf1\f51\fs20\ql company, business planning, raising capital, acquiring and developing our proprietary chemistry technology, identifying potential\plain\cf1\f51\fs20\ql product candidates and conducting preclinical studies of our product candidates and a clinical trial of our lead product candidate,\plain\cf1\f51\fs20\ql RA101495. To date, we have not generated any product revenue and have financed our operations primarily through the public\plain\cf1\f51\fs20\ql offering and the private placement of our securities and revenue from our collaboration with Merck. As of June\~30, 2017, we had\plain\cf1\f51\fs20\ql received an aggregate of $181.0\~million in net proceeds from the issuance of equity and debt securities and $17.5\~million in\plain\cf1\f51\fs20\ql payments in connection with our collaboration and license agreement with Merck (\u8220?Merck Agreement\u8221?). As of\plain\cf1\f51\fs20\ql June\~30, 2017, our principal source of liquidity was cash and cash equivalents, which totaled $96.6\~million.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 13{\*\bkmkstart PB_13_154833_3957}{\*\bkmkend PB_13_154833_3957}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql On October\~31, 2016, we completed an initial public offering (\u8220?IPO\u8221?), in which we issued and sold 7,049,230\plain\cf1\f51\fs20\ql shares of our common stock at a public offering price of $13.00 per share, resulting in net proceeds to us of $82.8 million after\plain\cf1\f51\fs20\ql deducting $6.4 million of underwriting discounts and commissions and offering costs of $2.4 million. On November\~29, 2016, we\plain\cf1\f51\fs20\ql completed the sale of an additional 1,057,385 shares of common stock to the underwriters under the underwriters\u8217? option\plain\cf1\f51\fs20\ql in the IPO to purchase additional shares of common stock at the public offering price of $13.00 per share, resulting in additional\plain\cf1\f51\fs20\ql net proceeds to us of $12.8 million after deducting underwriting discounts and commissions of $1.0 million.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql As of June\~30, 2017, we had an accumulated deficit of $92.8 million. Our net losses were $24.0 million and $9.9 million\plain\cf1\f51\fs20\ql for the six months ended June\~30, 2017 and 2016, respectively. We have incurred significant net operating losses in every year\plain\cf1\f51\fs20\ql since our inception and expect to continue to incur increasing net operating losses and significant expenses for the foreseeable\plain\cf1\f51\fs20\ql future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will\plain\cf1\f51\fs20\ql increase significantly as we:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql continue to advance our lead program, RA101495, through clinical development by establishing clinical\plain\li836\cf1\f51\fs20\ql proof-of-concept activity using convenient SC administration in PNH patients, particularly as we continue our Phase 2\plain\li836\cf1\f51\fs20\ql clinical trial in PNH;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql continue our current research programs and development activities;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql seek to identify additional research programs and additional product candidates;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql initiate preclinical testing and clinical trials for any product candidates we identify and develop, maintain, expand and\plain\li836\cf1\f51\fs20\ql protect our intellectual property portfolio;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql hire additional research, clinical and scientific personnel; and\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql incur additional costs associated with operating as a public company, including expanding our operational, finance and\plain\li836\cf1\f51\fs20\ql management teams.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We believe that, based on our current operating plan, our available funds will enable us to fund our operating expenses and\plain\cf1\f51\fs20\ql capital expenditure requirements into the fourth quarter of 2018. We do not expect to generate revenue from product sales unless\plain\cf1\f51\fs20\ql and until we successfully complete development and obtain regulatory approval for a product candidate, which we expect will\plain\cf1\f51\fs20\ql take a number of years and is subject to significant uncertainty. Additionally, we believe that our available funds will be\plain\cf1\f51\fs20\ql sufficient to enable us to obtain top-line data from our ongoing Phase\~2 clinical trials of RA101495 for the treatment of PNH,\plain\cf1\f51\fs20\ql initiate a Phase\~2 in rMG and a Phase\~1b supporting development in LN, as well as advance our other preclinical pipeline\plain\cf1\f51\fs20\ql programs. We expect that these funds will not, however, be sufficient to enable us to complete our Phase\~3 clinical study in\plain\cf1\f51\fs20\ql PNH. It is also possible that we will not achieve the progress that we expect with respect to RA101495 because the actual costs\plain\cf1\f51\fs20\ql and timing of clinical development activities are difficult to predict and are subject to substantial risks and delays. We will be\plain\cf1\f51\fs20\ql required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing\plain\cf1\f51\fs20\ql arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our\plain\cf1\f51\fs20\ql failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our\plain\cf1\f51\fs20\ql business strategy.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li286\fi-286\cf1\f51\fs20\b\ql Financial Overview\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Revenue\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We have derived all of our revenue to date from our collaboration and license agreement with Merck (\u8220?the Merck\plain\cf1\f51\fs20\ql Agreement\u8221?) which we entered into in April\~2013. Under the Merck Agreement, we collaborated with Merck and used our\plain\cf1\f51\fs20\ql proprietary drug discovery technology platform to identify orally available cyclic peptides for non-complement targets nominated\plain\cf1\f51\fs20\ql by Merck and provided specific research and development services. At the signing, Merck paid us an upfront, non-refundable,\plain\cf1\f51\fs20\ql license fee payment of $4.5\~million. In addition, during the research term, which ended in April\~2016, Merck reimbursed us for\plain\cf1\f51\fs20\ql research and development services provided by us in accordance with a pre-specified number of our full-time equivalent\plain\cf1\f51\fs20\ql employees (\u8220?FTEs\u8221?) working under the Merck Agreement. At the conclusion of the research term, Merck elected to\plain\cf1\f51\fs20\ql continue the development of a non-complement cardiovascular program target with a large market opportunity, for which we had\plain\cf1\f51\fs20\ql received $3.5\~million in preclinical milestone payments as of June\~30, 2017. We are also entitled to receive future aggregate\plain\cf1\f51\fs20\ql milestone payments of up to $61.5\~million and low-to-mid single digit percentage royalties on any future sales for this program\plain\cf1\f51\fs20\ql target. For additional information about the Merck Agreement, see Item\~8, \u8220?Financial Statements and Supplementary\plain\cf1\f51\fs20\ql Data\u8221? in our Annual Report on Form\~10-K for the year ended December\~31, 2016.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 14{\*\bkmkstart PB_14_154923_7056}{\*\bkmkend PB_14_154923_7056}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql To date, we have not generated any revenue from product sales and do not expect to do so in the near future. We expect\plain\cf1\f51\fs20\ql that our revenue will be less than our expenses for the foreseeable future and that we will experience increasing losses as we\plain\cf1\f51\fs20\ql continue our development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved\plain\cf1\f51\fs20\ql products. Our ability to generate revenue for each product candidate for which we receive regulatory approval will depend on\plain\cf1\f51\fs20\ql numerous factors, including competition, commercial manufacturing capability and market acceptance of our products.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Research and Development Expenses\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Research and development expenses consist primarily of costs incurred for our research activities, including development of\plain\cf1\f51\fs20\ql our proprietary chemistry technology platform, and our preclinical and clinical candidates, which include:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql employee-related expenses, including salaries, benefits, and stock-based compensation expense;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql expenses incurred under agreements with contract research organizations (\u8220?CROs\u8221?), contract\plain\li836\cf1\f51\fs20\ql manufacturing organizations (\u8220?CMOs\u8221?), and independent contractors that conduct research and\plain\li836\cf1\f51\fs20\ql development, preclinical and clinical activities on our behalf;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql costs of purchasing lab supplies and non-capital equipment used in our preclinical activities and in manufacturing\plain\li836\cf1\f51\fs20\ql preclinical study and clinical trial materials;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql consulting, licensing and professional fees related to research and development activities; and\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql facility costs, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance\plain\li836\cf1\f51\fs20\ql of facilities, insurance, and other supplies.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We expense research and development costs as incurred. We recognize costs for certain development activities, such as\plain\cf1\f51\fs20\ql preclinical studies and clinical trials, based on an evaluation of the progress to completion of specific tasks using information\plain\cf1\f51\fs20\ql provided to us by our vendors such as patient enrollment or clinical site activations for services received and efforts expended.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Research and development activities are central to our business model. We expect research and development costs to\plain\cf1\f51\fs20\ql increase significantly for the foreseeable future as our current development programs progress and new programs are added.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The following table sets forth our research and development expenses related to our product pipeline:\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx3388\clvertalb\cellx3549\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6750\clvertalb\cellx6911\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10017\clvertalb\cellx10042\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Three\~Months\~Ended\~June\~30,\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Six\~Months\~Ended\~June\~30,\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3388\clvertalb\cellx3549\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6750\clvertalb\cellx6911\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10017\clvertalb\cellx10042\trrh198\row}}}
{\trowd\clvertalb\cellx3388\clvertalb\cellx3549\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4952\clvertalb\cellx5369\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6749\clvertalb\cellx6910\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8274\clvertalb\cellx8652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10016\clvertalb\cellx10041\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3388\clvertalb\cellx3549\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4952\clvertalb\cellx5369\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6749\clvertalb\cellx6910\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8274\clvertalb\cellx8652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10016\clvertalb\cellx10041\trrh198\row}}}
{\trowd\clvertalb\cellx3388\clvertalb\cellx3549\clvertalb\cellx10018\clvertalb\cellx10043\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc (in\~thousands)\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx3388\clvertalb\cellx3549\clvertalb\cellx10018\clvertalb\cellx10043\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3388\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3966\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4951\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5368\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5785\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6909\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7287\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8272\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8650\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9028\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10013\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10038\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql RA101495\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 4,612\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,772\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 8,453\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 4,574\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3388\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3966\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4951\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5368\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5785\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6909\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7287\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8272\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8650\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9028\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10013\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10038\trrh248\row}}}
{\trowd\cellx3388\clvertalb\cellx3549\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4952\clvertalb\cellx5369\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6749\clvertalb\cellx6910\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8274\clvertalb\cellx8652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10016\clvertalb\cellx10041\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Other pipeline programs\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 870\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 225\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,504\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 292\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3388\clvertalb\cellx3549\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4952\clvertalb\cellx5369\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6749\clvertalb\cellx6910\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8274\clvertalb\cellx8652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10016\clvertalb\cellx10041\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3388\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4952\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5369\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6749\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6910\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8274\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8652\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10016\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10041\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Allocated costs\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 5,482\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,997\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 9,957\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 4,866\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3388\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4952\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5369\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6749\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6910\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8274\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8652\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10016\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10041\trrh248\row}}}
{\trowd\cellx3388\clvertalb\cellx3549\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4952\clvertalb\cellx5369\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6749\clvertalb\cellx6910\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8274\clvertalb\cellx8652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10016\clvertalb\cellx10041\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Unallocated costs\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 4,982\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,508\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 9,519\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 6,596\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx3388\clvertalb\cellx3549\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4952\clvertalb\cellx5369\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6749\clvertalb\cellx6910\clbrdrb\brdrs\brdrcf1\clvertalb\cellx8274\clvertalb\cellx8652\clbrdrb\brdrs\brdrcf1\clvertalb\cellx10016\clvertalb\cellx10041\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3388\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3966\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4951\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5368\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5785\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6909\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7287\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8272\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8650\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9028\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10013\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10038\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Total\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 10,464\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 6,505\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 19,476\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 11,462\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx3388\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3549\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3966\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4951\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5368\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5785\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6909\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7287\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8272\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8650\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9028\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10013\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx10038\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The expenses allocated to our product pipeline in the table above relate to CRO and CMO costs associated with our\plain\cf1\f51\fs20\ql pre-clinical studies and clinical trials. We do not allocate compensation, benefits and other employee-related expenses, costs\plain\cf1\f51\fs20\ql related to facilities, depreciation, share-based compensation, research and development support services, laboratory supplies and\plain\cf1\f51\fs20\ql certain other costs directly to programs.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Historically, we had not provided program costs because we have not tracked or recorded our research and development\plain\cf1\f51\fs20\ql expenses on a program-by-program basis. Beginning in the first quarter of 2017, we began to allocate costs related to our\plain\cf1\f51\fs20\ql third-party vendors directly to programs. Prior-period amounts in the table above were reclassified to conform to the current\plain\cf1\f51\fs20\ql period\u8217?s presentation.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 15{\*\bkmkstart PB_15_155124_5335}{\*\bkmkend PB_15_155124_5335}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Because of the numerous risks and uncertainties associated with product development, we cannot determine with certainty\plain\cf1\f51\fs20\ql the duration and completion costs of the current or future preclinical studies and clinical trials or if, when, or to what extent we\plain\cf1\f51\fs20\ql will generate revenues from the commercialization and sale of our product candidates. We may never succeed in achieving\plain\cf1\f51\fs20\ql regulatory approval for our product candidates. The duration, costs, and timing of preclinical studies and clinical trials and\plain\cf1\f51\fs20\ql development of our product candidates will depend on a variety of factors, including:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql successful completion of preclinical studies and Investigational New Drug-enabling studies;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql successful enrollment in, and completion of, clinical trials;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql receipt of marketing approvals from applicable regulatory authorities;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql obtaining and maintaining patent and trade secret protection and non-patent exclusivity;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql launching commercial sales of the product, if and when approved, whether alone or in collaboration with others;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql acceptance of the product, if and when approved, by patients, the medical community and third-party payors;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql effectively competing with other therapies and treatment options;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql a continued acceptable safety profile following approval;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql enforcing and defending intellectual property and proprietary rights and claims; and\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li836\fi-264\cf1\f53\fs20\ql ·\plain\li836\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li836\cf1\f51\fs20\ql achieving desirable medicinal properties for the intended indications.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with\plain\cf1\f51\fs20\ql the development of our current and future preclinical and clinical product candidates. For example, if the FDA, or another\plain\cf1\f51\fs20\ql regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the\plain\cf1\f51\fs20\ql completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical\plain\cf1\f51\fs20\ql studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of\plain\cf1\f51\fs20\ql preclinical and clinical development. We expect our research and development expenses to increase for the foreseeable future as\plain\cf1\f51\fs20\ql we continue the development of product candidates.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql General and Administrative Expenses\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql General and administrative expenses consist primarily of employee related expenses, including salaries, benefits, and\plain\cf1\f51\fs20\ql stock-based compensation, for personnel in executive, finance, facility operations and administrative functions. Other significant\plain\cf1\f51\fs20\ql costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and\plain\cf1\f51\fs20\ql corporate matters, and fees for accounting, tax and consulting services.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We anticipate that our general and administrative expenses will increase in the future to support continued research and\plain\cf1\f51\fs20\ql development activities, potential commercialization of our product candidates and increased costs of operating as a public\plain\cf1\f51\fs20\ql company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside\plain\cf1\f51\fs20\ql consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a\plain\cf1\f51\fs20\ql public company, including expenses related to services associated with maintaining compliance with exchange listing and\plain\cf1\f51\fs20\ql Securities and Exchange Commission (\u8220?the SEC\u8221?) requirements, director and officer insurance costs and investor\plain\cf1\f51\fs20\ql and public relations costs.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Other Income (Expense), Net\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Other income (expense), net primarily consists of interest income earned on our cash and cash equivalents and the increase\plain\cf1\f51\fs20\ql in fair value of preferred stock tranche rights.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li286\fi-286\cf1\f51\fs20\b\ql Critical Accounting Policies and Significant Judgments and Estimates\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Our discussion and analysis of our liquidity, capital resources and results of operations is based upon our condensed\plain\cf1\f51\fs20\ql consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The\plain\cf1\f51\fs20\ql preparation of these financial statements requires us to make certain estimates and assumptions that may affect the reported\plain\cf1\f51\fs20\ql amounts of assets and liabilities, the reported amounts of revenues and expenses during the reported periods and related\plain\cf1\f51\fs20\ql disclosures. These estimates and assumptions are monitored and analyzed by us for changes in facts and circumstances, and\plain\cf1\f51\fs20\ql material changes in these estimates could occur in the future. We base our estimates on our historical experience, trends in the\plain\cf1\f51\fs20\ql industry and various other factors that are\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 16{\*\bkmkstart PB_16_155214_5796}{\*\bkmkend PB_16_155214_5796}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql believed to be reasonable under the circumstances. Actual results may differ from our estimates under different assumptions or\plain\cf1\f51\fs20\ql conditions.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We believe that our application of the following accounting policies, each of which require significant judgments and\plain\cf1\f51\fs20\ql estimates on the part of management, is the most critical to aid in fully understanding and evaluating our reported financial\plain\cf1\f51\fs20\ql results: (1)\~revenue recognition, (2)\~accrued research and development expenses, and (3)\~stock-based compensation. Our critical\plain\cf1\f51\fs20\ql accounting policies are described in our Annual Report on Form\~10-K for the year ended December\~31, 2016.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li286\fi-286\cf1\f51\fs20\b\ql Result of Operations\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Three Months Ended June\~30, 2017 and 2016\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql The following table summarizes our results of operations:\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx2899\clvertalb\cellx3046\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6283\clvertalb\cellx6445\clvertalb\cellx7754\clvertalb\cellx7916\clvertalb\cellx9013\clvertalb\cellx9285\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Three\~Months\~Ended\~June\~30,\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx2899\clvertalb\cellx3046\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6283\clvertalb\cellx6445\clvertalb\cellx7754\clvertalb\cellx7916\clvertalb\cellx9013\clvertalb\cellx9285\trrh198\row}}}
{\trowd\clvertalb\cellx2899\clvertalb\cellx3046\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4471\clvertalb\cellx4888\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6282\clvertalb\cellx6444\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7753\clvertalb\cellx7915\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9012\clvertalb\cellx9284\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc $\~Change\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc %\~Change\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx2899\clvertalb\cellx3046\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4471\clvertalb\cellx4888\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6282\clvertalb\cellx6444\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7753\clvertalb\cellx7915\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9012\clvertalb\cellx9284\trrh198\row}}}
{\trowd\clvertalb\cellx2899\clvertalb\cellx3046\clvertalb\cellx9014\clvertalb\cellx9286\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc (in\~thousands,\~except\~percentages)\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx2899\clvertalb\cellx3046\clvertalb\cellx9014\clvertalb\cellx9286\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2899\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3046\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3463\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4470\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4887\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5304\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6443\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6775\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7752\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7914\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9011\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9283\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Revenue\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,044\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (3,044\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (100.0\cell\pard\plain\intbl\cf1\f51\fs20\ql )%\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2899\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3046\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3463\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4470\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4887\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5304\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6281\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6443\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6775\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7752\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7914\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9011\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9283\trrh248\row}}}
{\trowd\cellx2899\clvertalb\cellx3046\clvertalb\cellx4471\clvertalb\cellx4888\clvertalb\cellx6282\clvertalb\cellx6444\clvertalb\cellx7753\clvertalb\cellx7915\clvertalb\cellx9012\clvertalb\cellx9284\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Operating expenses:\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx2899\clvertalb\cellx3046\clvertalb\cellx4471\clvertalb\cellx4888\clvertalb\cellx6282\clvertalb\cellx6444\clvertalb\cellx7753\clvertalb\cellx7915\clvertalb\cellx9012\clvertalb\cellx9284\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2899\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3046\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4888\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6444\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7753\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7915\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9012\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9284\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Research and development\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 10,464\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 6,505\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 3,959\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 60.9\cell\pard\plain\intbl\cf1\f51\fs20\ql %\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2899\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3046\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4888\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6444\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7753\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7915\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9012\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9284\trrh248\row}}}
{\trowd\cellx2899\clvertalb\cellx3046\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4471\clvertalb\cellx4888\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6282\clvertalb\cellx6444\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7753\clvertalb\cellx7915\clvertalb\cellx9012\clvertalb\cellx9284\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql General and administrative\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,348\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,085\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,263\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 116.4\cell\pard\plain\intbl\cf1\f51\fs20\ql %\cell{
{\trowd\cellx2899\clvertalb\cellx3046\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4471\clvertalb\cellx4888\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6282\clvertalb\cellx6444\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7753\clvertalb\cellx7915\clvertalb\cellx9012\clvertalb\cellx9284\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2899\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3046\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4888\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6444\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7753\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7915\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9012\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9284\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Total operating expenses\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 12,812\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 7,590\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 5,222\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 68.8\cell\pard\plain\intbl\cf1\f51\fs20\ql %\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2899\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3046\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4888\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6444\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7753\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7915\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9012\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9284\trrh248\row}}}
{\trowd\cellx2899\clvertalb\cellx3046\clvertalb\cellx4471\clvertalb\cellx4888\clvertalb\cellx6282\clvertalb\cellx6444\clvertalb\cellx7753\clvertalb\cellx7915\clvertalb\cellx9012\clvertalb\cellx9284\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Loss from operations\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (12,812\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (4,546\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (8,266\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr 181.8\cell\pard\plain\intbl\cf1\f51\fs20\ql %\cell{
{\trowd\cellx2899\clvertalb\cellx3046\clvertalb\cellx4471\clvertalb\cellx4888\clvertalb\cellx6282\clvertalb\cellx6444\clvertalb\cellx7753\clvertalb\cellx7915\clvertalb\cellx9012\clvertalb\cellx9284\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2899\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3046\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4888\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6444\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7753\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7915\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9012\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9284\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Other income (expense), net\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 149\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (260\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr 409\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (157.3\cell\pard\plain\intbl\cf1\f51\fs20\ql )%\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2899\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3046\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4471\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4888\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6282\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6444\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7753\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7915\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9012\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9284\trrh248\row}}}
{\trowd\cellx2899\clvertalb\cellx3046\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx3463\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4470\clvertalb\cellx4887\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5304\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6281\clvertalb\cellx6443\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6775\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7752\clvertalb\cellx7914\clvertalb\cellx9011\clvertalb\cellx9283\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Net loss\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (12,663\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (4,806\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (7,857\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr 163.5\cell\pard\plain\intbl\cf1\f51\fs20\ql %\cell{
{\trowd\cellx2899\clvertalb\cellx3046\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx3463\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4470\clvertalb\cellx4887\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5304\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6281\clvertalb\cellx6443\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6775\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7752\clvertalb\cellx7914\clvertalb\cellx9011\clvertalb\cellx9283\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Revenue\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Revenue decreased by $3.0 million to zero for the three months ended June\~30, 2017, from $3.0 million for the three\plain\cf1\f51\fs20\ql months ended June\~30, 2016. This decrease was due to the expiration of the research term of the Merck Agreement in\~April\~2016.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Research and Development Expenses\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Research and development expenses increased by $4.0 million to $10.5 million for the three months ended June\~30, 2017,\plain\cf1\f51\fs20\ql from $6.5 million for the three months ended June\~30, 2016. This increase was attributable to a $2.5\~million increase in CRO and\plain\cf1\f51\fs20\ql CMO expenses for our pre-clinical studies and clinical trials, due primarily to our RA101495 program; a $1.0 million increase in\plain\cf1\f51\fs20\ql compensation, benefits, and other employee-related expenses due to higher average headcount to support our increased research\plain\cf1\f51\fs20\ql and development activities and 2017 salary increases; a $0.7 million increase in non-cash stock-based compensation, due\plain\cf1\f51\fs20\ql primarily to our annual grants made in February\~2017 and higher average stock price; and a $0.2 million increase in laboratory\plain\cf1\f51\fs20\ql supply and reagent expenses; partially offset by a $0.4 million net decrease in other expenses.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql General and Administrative Expenses\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql General and administrative expenses increased by $1.3 million to approximately $2.4 million for the three months ended\plain\cf1\f51\fs20\ql June\~30, 2017, from $1.1 million for the three months ended June\~30, 2016. This increase was attributable to a $0.4 million\plain\cf1\f51\fs20\ql increase in non-cash stock-based compensation due primarily to our annual grants made in February\~2017 and higher average\plain\cf1\f51\fs20\ql stock price; a $0.2 million increase in compensation, benefits, and other employee-related expenses due to higher average\plain\cf1\f51\fs20\ql headcount to support our increased activities and 2017 salary increases; a $0.2 million increase in patent costs; a $0.3 million\plain\cf1\f51\fs20\ql increase in insurance, legal and audit costs, primarily due to operating as a public company; and a $0.2 million net increase in\plain\cf1\f51\fs20\ql other expenses.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li286\fi-286\cf1\f51\fs20\b\i\ql Other Income (Expense), Net\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Other income (expense), net increased by $0.4 million to $0.1 million in other income, net for the three months ended\plain\cf1\f51\fs20\ql June\~30, 2017, from $0.3 million in other expense, net for the three months ended June\~30, 2016. This increase was due primarily\plain\cf1\f51\fs20\ql to the Series\~B-2 Preferred Stock Tranche Rights fair value adjustment of $0.2 million recorded during the three months ended\plain\cf1\f51\fs20\ql June\~30, 2016 and approximately a $0.1 million increase in interest income.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Six Months Ended June\~30, 2017 and 2016\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql The following table summarizes our results of operations:\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx2979\clvertalb\cellx3127\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6252\clvertalb\cellx6414\clvertalb\cellx7749\clvertalb\cellx7911\clvertalb\cellx9011\clvertalb\cellx9283\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Six\~Months\~Ended\~June\~30,\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx2979\clvertalb\cellx3127\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6252\clvertalb\cellx6414\clvertalb\cellx7749\clvertalb\cellx7911\clvertalb\cellx9011\clvertalb\cellx9283\trrh198\row}}}
{\trowd\clvertalb\cellx2979\clvertalb\cellx3127\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4515\clvertalb\cellx4893\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6251\clvertalb\cellx6413\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7748\clvertalb\cellx7910\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9010\clvertalb\cellx9282\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc $\~Change\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc %\~Change\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx2979\clvertalb\cellx3127\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4515\clvertalb\cellx4893\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6251\clvertalb\cellx6413\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7748\clvertalb\cellx7910\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9010\clvertalb\cellx9282\trrh198\row}}}
{\trowd\clvertalb\cellx2979\clvertalb\cellx3127\clvertalb\cellx9013\clvertalb\cellx9285\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc (in\~thousands,\~except\~percentages)\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx2979\clvertalb\cellx3127\clvertalb\cellx9013\clvertalb\cellx9285\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2979\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3127\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3505\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4515\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4893\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6251\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6413\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6745\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7910\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9282\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Revenue\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr \u8212?\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 4,928\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (4,928\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (100.0\cell\pard\plain\intbl\cf1\f51\fs20\ql )%\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2979\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3127\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3505\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4515\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4893\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx5271\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6251\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6413\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6745\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7910\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9282\trrh248\row}}}
{\trowd\cellx2979\clvertalb\cellx3127\clvertalb\cellx4515\clvertalb\cellx4893\clvertalb\cellx6251\clvertalb\cellx6413\clvertalb\cellx7748\clvertalb\cellx7910\clvertalb\cellx9010\clvertalb\cellx9282\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Operating expenses:\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx2979\clvertalb\cellx3127\clvertalb\cellx4515\clvertalb\cellx4893\clvertalb\cellx6251\clvertalb\cellx6413\clvertalb\cellx7748\clvertalb\cellx7910\clvertalb\cellx9010\clvertalb\cellx9282\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2979\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3127\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4515\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4893\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6251\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6413\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7910\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9282\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Research and development\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 19,476\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 11,462\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 8,014\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 69.9\cell\pard\plain\intbl\cf1\f51\fs20\ql %\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2979\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3127\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4515\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4893\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6251\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6413\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7910\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9282\trrh248\row}}}
{\trowd\cellx2979\clvertalb\cellx3127\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4515\clvertalb\cellx4893\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6251\clvertalb\cellx6413\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7748\clvertalb\cellx7910\clvertalb\cellx9010\clvertalb\cellx9282\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql General and administrative\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 4,817\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,376\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 2,441\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 102.7\cell\pard\plain\intbl\cf1\f51\fs20\ql %\cell{
{\trowd\cellx2979\clvertalb\cellx3127\clbrdrb\brdrs\brdrcf1\clvertalb\cellx4515\clvertalb\cellx4893\clbrdrb\brdrs\brdrcf1\clvertalb\cellx6251\clvertalb\cellx6413\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7748\clvertalb\cellx7910\clvertalb\cellx9010\clvertalb\cellx9282\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2979\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3127\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4515\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4893\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6251\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6413\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7910\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9282\trrh248
\pard\plain\intbl\li660\fi-220\cf1\f51\fs20\ql Total operating expenses\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 24,293\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 13,838\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 10,455\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 75.6\cell\pard\plain\intbl\cf1\f51\fs20\ql %\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2979\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3127\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4515\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4893\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6251\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6413\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7910\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9282\trrh248\row}}}
{\trowd\cellx2979\clvertalb\cellx3127\clvertalb\cellx4515\clvertalb\cellx4893\clvertalb\cellx6251\clvertalb\cellx6413\clvertalb\cellx7748\clvertalb\cellx7910\clvertalb\cellx9010\clvertalb\cellx9282\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Loss from operations\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (24,293\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (8,910\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (15,383\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr 172.6\cell\pard\plain\intbl\cf1\f51\fs20\ql %\cell{
{\trowd\cellx2979\clvertalb\cellx3127\clvertalb\cellx4515\clvertalb\cellx4893\clvertalb\cellx6251\clvertalb\cellx6413\clvertalb\cellx7748\clvertalb\cellx7910\clvertalb\cellx9010\clvertalb\cellx9282\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2979\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3127\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4515\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4893\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6251\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6413\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7910\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9282\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Other income (expense), net\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 270\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (952\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr 1,222\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (128.4\cell\pard\plain\intbl\cf1\f51\fs20\ql )%\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx2979\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx3127\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4515\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx4893\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6251\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6413\clbrdrb\brdrs\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7748\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7910\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9010\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9282\trrh248\row}}}
{\trowd\cellx2979\clvertalb\cellx3127\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx3505\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4515\clvertalb\cellx4893\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5271\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6251\clvertalb\cellx6413\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6745\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7748\clvertalb\cellx7910\clvertalb\cellx9010\clvertalb\cellx9282\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Net loss\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (24,023\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (9,862\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (14,161\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr 143.6\cell\pard\plain\intbl\cf1\f51\fs20\ql %\cell{
{\trowd\cellx2979\clvertalb\cellx3127\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx3505\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx4515\clvertalb\cellx4893\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx5271\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6251\clvertalb\cellx6413\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx6745\clbrdrb\brdrdb\brdrcf1\clvertalb\cellx7748\clvertalb\cellx7910\clvertalb\cellx9010\clvertalb\cellx9282\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 17{\*\bkmkstart PB_17_155710_2897}{\*\bkmkend PB_17_155710_2897}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Revenue\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Revenue decreased by $4.9 million to zero for the six months ended June\~30, 2017, from $4.9 million for the six months\plain\cf1\f51\fs20\ql ended June\~30, 2016. This decrease was due to the expiration of the research term of the Merck Agreement in\~April\~2016.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Research and Development Expenses\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Research and development expenses increased by $8.0 million to $19.5 million for the six months ended June\~30, 2017,\plain\cf1\f51\fs20\ql from $11.5 million for the six months ended June\~30, 2016. This increase was attributable to a $5.1\~million increase in CRO and\plain\cf1\f51\fs20\ql CMO expenses for our pre-clinical studies and clinical trials, related primarily to our RA101495 program; a $1.7 million increase\plain\cf1\f51\fs20\ql in compensation, benefits, and other employee-related expenses due to higher average headcount to support our increased\plain\cf1\f51\fs20\ql research and development activities and 2017 salary increases; a $1.2 million increase in non-cash stock-based compensation due\plain\cf1\f51\fs20\ql primarily to our annual grants made in February\~2017 and higher average stock price; and a $0.4 million increase in laboratory\plain\cf1\f51\fs20\ql supply and reagent expenses; partially offset by a $0.3 million decrease in consulting and legal fees and approximately a $0.1\plain\cf1\f51\fs20\ql million net decrease in other expenses.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql General and Administrative Expenses\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql General and administrative expenses increased by $2.4 million to $4.8 million for the six months ended June\~30, 2017,\plain\cf1\f51\fs20\ql from $2.4 million for the six months ended June\~30, 2016. This increase was attributable to a $0.8 million increase in non-cash\plain\cf1\f51\fs20\ql stock-based compensation due primarily to our annual grants made in February\~2017 and higher average stock price; a $0.6\plain\cf1\f51\fs20\ql million increase in compensation, benefits, and other employee-related expenses due primarily to higher average headcount to\plain\cf1\f51\fs20\ql support our increased activities and 2017 salary increases; a $0.4 million increase in patent costs; a $0.6 million increase in\plain\cf1\f51\fs20\ql insurance, legal and audit costs, primarily due to operating as a public company; and a $0.3 million net increase in other\plain\cf1\f51\fs20\ql expenses; partially offset by a $0.3 million decrease in consulting and professional fees due primarily to lower costs associated\plain\cf1\f51\fs20\ql with market research.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li286\fi-286\cf1\f51\fs20\b\i\ql Other Income (Expense), Net\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Other income (expense), net increased by $1.2 million to $0.3 million in other income, net for the six months ended\plain\cf1\f51\fs20\ql June\~30, 2017, from approximately $0.9 million in other expense, net for the six months ended June\~30, 2016. This increase was\plain\cf1\f51\fs20\ql due primarily to the Series\~B-2 Preferred Stock Tranche Rights fair value adjustment of $1.0 million recorded during the six\plain\cf1\f51\fs20\ql months ended June\~30, 2016 and a $0.3 million increase in interest income.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li286\fi-286\cf1\f51\fs20\b\ql Liquidity and Capital Resources\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Overview\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi440\cf1\f51\fs20\ql We have funded our operations from inception through June\~30, 2017 primarily through the public offering and the private\plain\cf1\f51\fs20\ql placement of our securities and revenue from our collaboration with Merck. As of June\~30, 2017, we had received an aggregate\plain\cf1\f51\fs20\ql of $181.0 million in net proceeds from the issuance of equity and debt securities and $17.5 million in payments in connection\plain\cf1\f51\fs20\ql with our collaboration and license agreement with Merck. As of June\~30, 2017, we had cash and cash equivalents of $96.6\plain\cf1\f51\fs20\ql million.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li286\fi-286\cf1\f51\fs20\b\ql Cash Flows\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The following table provides information regarding our cash flows for the six months ended June\~30, 2017 and 2016:\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clvertalb\cellx6089\clvertalb\cellx6264\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9194\clvertalb\cellx9286\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc Six\~Months\~Ended\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx6089\clvertalb\cellx6264\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9194\clvertalb\cellx9286\trrh198\row}}}
{\trowd\clvertalb\cellx6089\clvertalb\cellx6264\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7603\clvertalb\cellx7859\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9193\clvertalb\cellx9285\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2017\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc 2016\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx6089\clvertalb\cellx6264\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7603\clvertalb\cellx7859\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9193\clvertalb\cellx9285\trrh198\row}}}
{\trowd\clvertalb\cellx6089\clvertalb\cellx6264\clvertalb\cellx9194\clvertalb\cellx9286\trrh198
\pard\plain\intbl\cf1\f51\fs2\b\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell\pard\plain\intbl\cf1\f51\fs16\b\qc (in\~thousands)\cell\pard\plain\intbl\cf1\f51\fs2\b\qc \~\cell{
{\trowd\clvertalb\cellx6089\clvertalb\cellx6264\clvertalb\cellx9194\clvertalb\cellx9286\trrh198\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6089\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6264\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7603\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7859\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9193\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9285\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Net cash provided by (used in):\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\qr \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6089\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6264\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7603\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7859\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9193\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9285\trrh248\row}}}
{\trowd\cellx6089\clvertalb\cellx6264\clvertalb\cellx6520\clvertalb\cellx7602\clvertalb\cellx7858\clvertalb\cellx8114\clvertalb\cellx9192\clvertalb\cellx9284\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Operating activities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (20,914\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (5,324\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\cellx6089\clvertalb\cellx6264\clvertalb\cellx6520\clvertalb\cellx7602\clvertalb\cellx7858\clvertalb\cellx8114\clvertalb\cellx9192\clvertalb\cellx9284\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6089\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6264\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7603\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7859\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9193\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9285\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Investing activities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr (1,128\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\qr (3,088\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6089\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6264\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7603\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7859\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9193\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9285\trrh248\row}}}
{\trowd\cellx6089\clvertalb\cellx6264\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7603\clvertalb\cellx7859\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9193\clvertalb\cellx9285\trrh248
\pard\plain\intbl\li440\fi-220\cf1\f51\fs20\ql Financing activities\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 835\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\qr 29,272\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx6089\clvertalb\cellx6264\clbrdrb\brdrs\brdrcf1\clvertalb\cellx7603\clvertalb\cellx7859\clbrdrb\brdrs\brdrcf1\clvertalb\cellx9193\clvertalb\cellx9285\trrh248\row}}}
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6089\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6264\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6520\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7602\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7858\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8114\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9192\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9284\trrh248
\pard\plain\intbl\li220\fi-220\cf1\f51\fs20\ql Net increase (decrease) in cash\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr (21,207\cell\pard\plain\intbl\cf1\f51\fs20\ql )\cell\pard\plain\intbl\cf1\f51\fs20\ql $\cell\pard\plain\intbl\cf1\f51\fs20\qr 20,860\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clshdng100\clcfpat11\clcbpat11\cellx6089\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6264\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx6520\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7602\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx7858\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx8114\clbrdrb\brdrdb\brdrcf1\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9192\clvertalb\clshdng100\clcfpat11\clcbpat11\cellx9284\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 18{\*\bkmkstart PB_18_155858_3020}{\*\bkmkend PB_18_155858_3020}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Net Cash Used in Operating Activities\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Cash flows used in operating activities represent the cash receipts and disbursements related to all of our activities other\plain\cf1\f51\fs20\ql than investing and financing activities. Operating cash flow is derived by adjusting our net loss for (1)\~non-cash operating items\plain\cf1\f51\fs20\ql such as depreciation and amortization, stock-based compensation and changes in fair value of preferred stock tranche rights as\plain\cf1\f51\fs20\ql well as (2)\~changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash\plain\cf1\f51\fs20\ql associated with transactions and when they are recognized in our results of operations.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Net cash used in operating activities was $20.9\~million for the six months ended June\~30, 2017 compared to $5.3\~million\plain\cf1\f51\fs20\ql for the six months ended June\~30, 2016. The increase in net cash used in operations was attributable primarily to a $14.2 million\plain\cf1\f51\fs20\ql increase in our net loss as a result of higher operating expenses, primarily in connection with our pre-clinical studies and clinical\plain\cf1\f51\fs20\ql trials related to our RA101495 program and other research and development pipeline programs; and a decrease in operating assets\plain\cf1\f51\fs20\ql and liabilities; partially offset by higher non-cash expenses, including depreciation, amortization and stock-based compensation.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Net Cash Used in Investing Activities\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Net cash used in investing activities was $1.1\~million for the six months ended June\~30, 2017 compared to $3.1\~million for\plain\cf1\f51\fs20\ql the six months ended June\~30, 2016. The decrease in cash used in investing activities was due primarily to a reduction in\plain\cf1\f51\fs20\ql purchases of property and equipment.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Net Cash Provided by Financing Activities\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Net cash provided by financing activities was $0.8 million for the six months ended June\~30, 2017 compared to $29.3\plain\cf1\f51\fs20\ql million for the six months ended June\~30, 2016. The decrease in cash provided by financing activities was due primarily to the\plain\cf1\f51\fs20\ql Series\~B-2 Preferred Stock financing completed in June\~2016, which resulted in net proceeds of $29.2 million; partially offset by\plain\cf1\f51\fs20\ql proceeds of $0.7 million from the disgorgement of a stockholder\u8217?s short-swing profits and higher proceeds from exercises\plain\cf1\f51\fs20\ql of stock options.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 19{\*\bkmkstart PB_19_155915_7748}{\*\bkmkend PB_19_155915_7748}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Funding Requirements\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We expect our expenses to increase in connection with our ongoing activities, particularly as we continue our Phase 2\plain\cf1\f51\fs20\ql clinical trials of RA101495 in PNH, initiate clinical trials of RA101495 in additional indications, including rMG and LN, advance\plain\cf1\f51\fs20\ql the development of pipeline programs, initiate new research and preclinical development efforts and seek marketing approval for\plain\cf1\f51\fs20\ql any product candidates that we successfully develop. In addition, if we obtain marketing approval for any of our product\plain\cf1\f51\fs20\ql candidates, we expect to incur significant commercialization expenses related to establishing sales, marketing, distribution and\plain\cf1\f51\fs20\ql other commercial infrastructure to commercialize such products. Furthermore, we anticipate increased costs associated with being\plain\cf1\f51\fs20\ql and operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our\plain\cf1\f51\fs20\ql continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce\plain\cf1\f51\fs20\ql or eliminate our research and development programs or future commercialization efforts.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql On October\~31, 2016, we completed an IPO, in which we issued and sold 7,049,230 shares of our common stock at a\plain\cf1\f51\fs20\ql public offering price of $13.00 per share, resulting in net proceeds to us of $82.8 million after deducting $6.4 million of\plain\cf1\f51\fs20\ql underwriting discounts and commissions and offering costs of $2.4 million. On November\~29, 2016, we completed the sale of an\plain\cf1\f51\fs20\ql additional 1,057,385 shares of common stock to the underwriters under the underwriters\u8217? option in the IPO to purchase\plain\cf1\f51\fs20\ql additional shares of common stock at the public offering price of $13.00 per share, resulting in additional net proceeds to us of\plain\cf1\f51\fs20\ql $12.8 million after deducting underwriting discounts and commissions. We believe that, based on our current operating plan, our\plain\cf1\f51\fs20\ql existing cash and cash equivalents as of June\~30, 2017, will enable us to fund our operating expenses and capital expenditure\plain\cf1\f51\fs20\ql requirements into the fourth quarter of 2018. We have based our projections of operating capital requirements on assumptions\plain\cf1\f51\fs20\ql that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the\plain\cf1\f51\fs20\ql numerous risks and uncertainties associated with the development and commercialization of RA101495 and the research,\plain\cf1\f51\fs20\ql development and commercialization of other potential product candidates, we are unable to estimate the exact amount of our\plain\cf1\f51\fs20\ql operating capital requirements. Our future capital requirements will depend on many factors, including:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li1122\fi-264\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the scope, progress, timing, costs and results of clinical trials of RA101495;\par\pard\plain\li1122\fi-264\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql research and preclinical development efforts for any future product candidates that we may develop;\par\pard\plain\li1122\fi-264\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql our ability to enter into and the terms and timing of any collaborations, licensing agreements or other\plain\li1122\cf1\f51\fs20\ql arrangements;\par\pard\plain\li1122\fi-264\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the number of future product candidates that we pursue and their development requirements;\par\pard\plain\li1122\fi-264\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the outcome, timing and costs of seeking regulatory approvals;\par\pard\plain\li1122\fi-264\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the costs of commercialization activities for any of our product candidates that receive marketing approval to the\plain\li1122\cf1\f51\fs20\ql extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing\plain\li1122\cf1\f51\fs20\ql product sales, marketing, distribution and manufacturing capabilities;\par\pard\plain\li1122\fi-264\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql subject to receipt of marketing approval, revenue, if any, received from commercial sales of our current and future\plain\li1122\cf1\f51\fs20\ql product candidates;\par\pard\plain\li1122\fi-264\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql our headcount growth and associated costs as we expand our research and development and establish a commercial\plain\li1122\cf1\f51\fs20\ql infrastructure;\par\pard\plain\li1122\fi-264\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual\plain\li1122\cf1\f51\fs20\ql property rights and defending against intellectual property related claims; and\par\pard\plain\li1122\fi-264\cf1\f53\fs20\ql ·\plain\li1122\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1122\cf1\f51\fs20\ql the costs of operating as a public company.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming,\plain\cf1\f51\fs20\ql expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results\plain\cf1\f51\fs20\ql required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not\plain\cf1\f51\fs20\ql achieve commercial success. Accordingly, we will need to continue to rely on additional financing to achieve our business\plain\cf1\f51\fs20\ql objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a\plain\cf1\f51\fs20\ql combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that\plain\cf1\f51\fs20\ql we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing\plain\cf1\f51\fs20\ql stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect\plain\cf1\f51\fs20\ql the rights of a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or\plain\cf1\f51\fs20\ql restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring\plain\cf1\f51\fs20\ql dividends.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may\plain\cf1\f51\fs20\ql have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant\plain\cf1\f51\fs20\ql licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings\plain\cf1\f51\fs20\ql when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization\plain\cf1\f51\fs20\ql efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 20{\*\bkmkstart PB_20_160419_7091}{\*\bkmkend PB_20_160419_7091}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\ql Contractual Commitments and Obligations\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The disclosure of our contractual obligations and commitments was reported in our Annual Report on Form\~10-K for the\plain\cf1\f51\fs20\ql year ended December\~31, 2016. There have been no material changes from the contractual commitments and obligations\plain\cf1\f51\fs20\ql previously disclosed in our Annual Report on Form\~10-K.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\ql Off-Balance Sheet Arrangements\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql As of June\~30, 2017, we did not have any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii)\~of\plain\cf1\f51\fs20\ql SEC Regulation S-K promulgated under the Exchange Act.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\ql Recent Accounting Pronouncements\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql For a discussion of recently adopted or issued accounting pronouncements please refer to Note 1, \u8220?Nature of\plain\cf1\f51\fs20\ql Business and Basis of Presentation\u8221? in this Quarterly Report on Form\~10-Q.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\ql Jumpstart our Business Startups Act of 2012 \~Act\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The Jumpstart our Business Startups Act of 2012 (\u8220?the JOBS Act\u8221?) permits an \u8220?emerging growth\plain\cf1\f51\fs20\ql company\u8221? such as us to take advantage of an extended transition period to comply with new or revised accounting\plain\cf1\f51\fs20\ql standards applicable to public companies. We have chosen to \u8220?opt out\u8221? of this provision and will comply with new\plain\cf1\f51\fs20\ql or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period\plain\cf1\f51\fs20\ql under the JOBS Act is irrevocable.\par\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart item_1_3_3}{\*\bkmkend item_1_3_3}\par\pard\plain\li286\fi-286\cf1\f51\fs20\b\ql Item 3. Quantitative and Qualitative Disclosures About Market Risk{\*\bkmkstart Item3_QuantitativeandQualitative}{\*\bkmkend Item3_QuantitativeandQualitative}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Interest Rate Risk\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We are exposed to market risk related to changes in interest rates. As of June\~30, 2017, we had cash and cash equivalents\plain\cf1\f51\fs20\ql of $96.6 million, consisting primarily of money market funds. Our primary exposure to market risk is interest rate sensitivity,\plain\cf1\f51\fs20\ql which is affected by changes in the general level of U.S. interest rates, particularly because our cash equivalents are in held in\plain\cf1\f51\fs20\ql short-term money market funds. Due to short-term duration of our investment portfolio and the low risk profile of our\plain\cf1\f51\fs20\ql investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of\plain\cf1\f51\fs20\ql our portfolio.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Foreign Currency Risk\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We are also exposed to market risk related to changes in foreign currency exchange rates. From time to time, we engage\plain\cf1\f51\fs20\ql contract research organizations, or CROs, and investigational sites globally. We are therefore subject to fluctuations in foreign\plain\cf1\f51\fs20\ql currency rates in connection with these engagements. We do not currently hedge our foreign currency exchange rate risk. As of\plain\cf1\f51\fs20\ql June\~30, 2017, we had minimal or no assets or liabilities denominated in foreign currencies.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Effects of Inflation\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We do not believe that inflation and changing prices during the three months ended June\~30, 2017 had a significant impact\plain\cf1\f51\fs20\ql on our results of operations or financial condition.\par\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart item_1_3_4}{\*\bkmkend item_1_3_4}\par\pard\plain\li286\fi-286\cf1\f51\fs20\b\ql Item 4. Controls and Procedures{\*\bkmkstart Item4_ControlsandProcedures_0402}{\*\bkmkend Item4_ControlsandProcedures_0402}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\ql (a)\~\~\~Evaluation of Disclosure Controls and Procedures\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql We have established disclosure controls and procedures designed to ensure that information required to be disclosed in the\plain\cf1\f51\fs20\ql reports that we file or submits under the Securities Exchange Act of 1934, as amended (Exchange Act) is recorded, processed,\plain\cf1\f51\fs20\ql summarized and reported within the time periods specified in the SEC\u8217?s rules\~and forms and is accumulated and\plain\cf1\f51\fs20\ql communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial\plain\cf1\f51\fs20\ql officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial\plain\cf1\f51\fs20\ql Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules\~13a-15(e)\~and\plain\cf1\f51\fs20\ql 15d-15(e)\~under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form\~10-Q. Management\plain\cf1\f51\fs20\ql recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable\plain\cf1\f51\fs20\ql assurance of achieving their objectives. Our disclosure controls and procedures have been designed to provide reasonable\plain\cf1\f51\fs20\ql assurance of achieving their\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 21{\*\bkmkstart PB_21_160419_455}{\*\bkmkend PB_21_160419_455}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql objectives. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure\plain\cf1\f51\fs20\ql controls and procedures were effective at the reasonable assurance level as of June\~30, 2017.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\ql (b)\plain\cf1\f51\fs20\ql \~\~\~\~\~\~\~\~\~\~\plain\cf1\f51\fs20\b\ql Changes in Internal Controls\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql There were no changes in the Company\u8217?s internal control over financial reporting identified in connection with the\plain\cf1\f51\fs20\ql evaluation required by paragraph\~(d)\~of the Exchange Act Rules\~13a-15 or 15d-15 that occurred during the quarter ended\plain\cf1\f51\fs20\ql June\~30, 2017 that materially affected, or were reasonably likely to materially affect, the Company\u8217?s internal control over\plain\cf1\f51\fs20\ql financial reporting.\par\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart part_1_2_2}{\*\bkmkend part_1_2_2}\par\pard\plain\cf1\f51\fs20\b\ql PART\~II \u8212? OTHER INFORMATION{\*\bkmkstart PARTIIOTHERINFORMATION_040259}{\*\bkmkend PARTIIOTHERINFORMATION_040259}\par\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart item_1_3_5}{\*\bkmkend item_1_3_5}\par\pard\plain\li1078\fi-1078\cf1\f51\fs20\b\ql Item\~1A.\plain\li1078\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1078\cf1\f51\fs20\b\ql Risk Factors{\*\bkmkstart Item1A_RiskFactors_040305}{\*\bkmkend Item1A_RiskFactors_040305}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In addition to the other information set forth in this Quarterly Report on Form\~10-Q, careful consideration should be given\plain\cf1\f51\fs20\ql to the risk factors discussed in Item 1A, \u8220?Risk Factors\u8221? in our Annual Report on Form\~10-K for the year ended\plain\cf1\f51\fs20\ql December\~31, 2016, which could materially affect our business, financial condition, and/or future results. The risks described in\plain\cf1\f51\fs20\ql our Annual Report on Form\~10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or\plain\cf1\f51\fs20\ql that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating\plain\cf1\f51\fs20\ql results. There have been no material changes to the risk factors set forth in our Annual Report on Form\~10-K for the year ended\plain\cf1\f51\fs20\ql December\~31, 2016.\par\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart item_1_3_6}{\*\bkmkend item_1_3_6}\par\pard\plain\li1078\fi-1078\cf1\f51\fs20\b\ql Item\~2.\plain\li1078\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1078\cf1\f51\fs20\b\ql Unregistered Sales of Equity Securities and Use of Proceeds{\*\bkmkstart Item2_UnregisteredSalesofEquityS}{\*\bkmkend Item2_UnregisteredSalesofEquityS}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Recent Sales of Unregistered Securities\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql None.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\i\ql Use of Proceeds\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql In October\~2016, we issued and sold 7,049,230 shares of our common stock in our IPO and, in November\~2016, we issued\plain\cf1\f51\fs20\ql and sold 1,057,385 shares of common stock to the underwriters under the underwriters\u8217? option to purchase additional\plain\cf1\f51\fs20\ql shares of common stock, at a public offering price of $13.00 per share, for aggregate gross proceeds of $105.4 million. All of the\plain\cf1\f51\fs20\ql shares issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on Form\~S-1\plain\cf1\f51\fs20\ql (File No.\~333- 213917), which was declared effective by the SEC on October\~26, 2016. Credit Suisse Securities (USA) LLC,\plain\cf1\f51\fs20\ql Jeffries LLC and BMO Capital Markets Corp. acted as joint book-running managers of the offering and as representatives of the\plain\cf1\f51\fs20\ql underwriters.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql The net proceeds to us, after deducting underwriting discounts and commissions of $7.4 million and offering expenses of\plain\cf1\f51\fs20\ql $2.4 million, were approximately $95.6 million. No offering expenses were paid directly or indirectly to any of our directors or\plain\cf1\f51\fs20\ql officers, or their associates, or persons owning 10.0% or more of any class of our equity securities or to any other affiliates.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\fi550\cf1\f51\fs20\ql As of June\~30, 2017, no net offering proceeds from our IPO had been used.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 22{\*\bkmkstart PB_22_160419_4141}{\*\bkmkend PB_22_160419_4141}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\ql \~{\*\bkmkstart item_1_3_7}{\*\bkmkend item_1_3_7}\par\pard\plain\li1078\fi-1078\cf1\f51\fs20\b\ql Item\~6.\plain\li1078\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li1078\cf1\f51\fs20\b\ql Exhibits{\*\bkmkstart Item6_Exhibits_055350}{\*\bkmkend Item6_Exhibits_055350}\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh495
\pard\plain\intbl\cf1\f51\fs20\qr 31.1\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql Certification of Chief Executive Officer pursuant to Rules\~13a-14(a)\~or 15d-14(a)\~of the Securities Exchange\plain\intbl\cf1\f51\fs20\ql Act of 1934, as adopted pursuant to Section\~302 of the Sarbanes-Oxley Act of 2002.\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh495\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh495
\pard\plain\intbl\cf1\f51\fs20\qr 31.2\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql Certification of Chief Financial Officer pursuant to Rules\~13a-14(a)\~or 15d-14(a)\~of the Securities Exchange\plain\intbl\cf1\f51\fs20\ql Act of 1934, as adopted pursuant to Section\~302 of the Sarbanes-Oxley Act of 2002.\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh495\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh743
\pard\plain\intbl\cf1\f51\fs20\qr 32.1*\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql Certifications pursuant to 18 U.S.C. Section\~1350, as adopted pursuant to Section\~906 of The Sarbanes-Oxley\plain\intbl\cf1\f51\fs20\ql Act of 2002, by Douglas A. Treco, Ph.D., President and Chief Executive Officer of the Company, and David C.\plain\intbl\cf1\f51\fs20\ql Lubner, Executive Vice President and Chief Financial Officer of the Company.\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh743\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr 101.INS\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql Extensible Business Reporting Language (XBRL) Instance Document.\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr 101.SCH\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql XBRL Schema Document.\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr 101.CAL\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql XBRL Calculation Linkbase Document.\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr 101.LAB\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql XBRL Labels Linkbase Document.\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr 101.PRE\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql XBRL Presentation Linkbase Document.\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\qr 101.DEF\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql XBRL Definition Linkbase Document.\cell{
{\trowd\trqc\cellx1116\cellx1476\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par\par\pard\plain\cf1\f51\fs20\ql *\~ The certifications furnished in Exhibit\~32.1 hereto are deemed to accompany this Quarterly Report on Form\~10-Q and will not\plain\cf1\f51\fs20\ql be deemed \u8220?filed\u8221? for purposes of Section\~18 of the Securities Exchange Act of 1934, as amended, except to the\plain\cf1\f51\fs20\ql extent that the Registrant specifically incorporates it by reference. Such certifications will not be deemed to be incorporated by\plain\cf1\f51\fs20\ql reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended,\plain\cf1\f51\fs20\ql except to the extent that the Registrant specifically incorporates it by reference.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 23{\*\bkmkstart PB_23_160638_8627}{\*\bkmkend PB_23_160638_8627}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page
\par\pard\plain\fs16\pard\plain\ul{\field{\*\fldinst HYPERLINK \\l "TableOfContents" }{\*\fldrslt\cf3\f51\fs20\ql Table of Contents}}\par\pard\plain\cf1\f51\fs20\qc \~{\*\bkmkstart part_1_2_3}{\*\bkmkend part_1_2_3}\par\pard\plain\cf1\f51\fs20\b\qc SIGNATURES{\*\bkmkstart SIGNATURES_040035}{\*\bkmkend SIGNATURES_040035}\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its\plain\cf1\f51\fs20\ql behalf by the undersigned, thereunto duly authorized.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Dated: August\~9, 2017\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\cellx4923\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql RA PHARMACEUTICALS,\~INC.\cell{
{\trowd\cellx4923\cellx10799\trrh248\row}}}
{\trowd\cellx4923\cellx6193\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\cellx4923\cellx6193\cellx10799\trrh248\row}}}
{\trowd\cellx4923\cellx6193\clbrdrb\brdrs\brdrcf1\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql By:\cell\pard\plain\intbl\cf1\f51\fs20\ql /s/ Douglas A. Treco\cell{
{\trowd\cellx4923\cellx6193\clbrdrb\brdrs\brdrcf1\cellx10799\trrh248\row}}}
{\trowd\cellx4923\cellx6193\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql Douglas A. Treco, Ph.D.\cell{
{\trowd\cellx4923\cellx6193\cellx10799\trrh248\row}}}
{\trowd\cellx4923\cellx6193\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql President and Chief Executive Officer\cell{
{\trowd\cellx4923\cellx6193\cellx10799\trrh248\row}}}
{\trowd\cellx4923\cellx6193\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql (Principal Executive Officer)\cell{
{\trowd\cellx4923\cellx6193\cellx10799\trrh248\row}}}
{\trowd\cellx4923\cellx6193\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\cellx4923\cellx6193\cellx10799\trrh248\row}}}
{\trowd\cellx4923\cellx6193\clbrdrb\brdrs\brdrcf1\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql By:\cell\pard\plain\intbl\cf1\f51\fs20\ql /s/ David C. Lubner\cell{
{\trowd\cellx4923\cellx6193\clbrdrb\brdrs\brdrcf1\cellx10799\trrh248\row}}}
{\trowd\cellx4923\cellx6193\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql David C. Lubner\cell{
{\trowd\cellx4923\cellx6193\cellx10799\trrh248\row}}}
{\trowd\cellx4923\cellx6193\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql Executive Vice President and Chief Financial Officer\cell{
{\trowd\cellx4923\cellx6193\cellx10799\trrh248\row}}}
{\trowd\cellx4923\cellx6193\cellx10799\trrh248
\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql (Principal Financial Officer)\cell{
{\trowd\cellx4923\cellx6193\cellx10799\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\qc 24{\*\bkmkstart PB_24_160026_8809}{\*\bkmkend PB_24_160026_8809}\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart doc_1_2}{\*\bkmkend doc_1_2}\par\pard\plain\cf1\f51\fs20\b\qr Exhibit\~31.1\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO\par\pard\plain\cf1\f51\fs20\b\qc RULE 13a-14(a)\~/ RULE 15d-14(a)\~OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql I, Douglas A. Treco, certify that:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\ql 1.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\ql I have reviewed this Quarterly Report on Form\~10-Q of Ra Pharmaceuticals,\~Inc.;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\ql 2.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\ql Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact\plain\li264\cf1\f51\fs20\ql necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading\plain\li264\cf1\f51\fs20\ql with respect to the period covered by this report;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\ql 3.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\ql Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all\plain\li264\cf1\f51\fs20\ql material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods\plain\li264\cf1\f51\fs20\ql presented in this report;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\ql 4.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\ql The registrant\u8217?s other certifying officer and I are responsible for establishing and maintaining disclosure controls and\plain\li264\cf1\f51\fs20\ql procedures (as defined in Exchange Act Rules\~13a-15(e)\~and 15d-15(e)) for the registrant and have:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql a.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed\plain\li550\cf1\f51\fs20\ql under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,\plain\li550\cf1\f51\fs20\ql is made known to us by others within those entities, particularly during the period in which this report is being prepared;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql b.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql c.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql Evaluated the effectiveness of the registrant\u8217?s disclosure controls and procedures and presented in this report our\plain\li550\cf1\f51\fs20\ql conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this\plain\li550\cf1\f51\fs20\ql report based on such evaluation; and\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql d.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql Disclosed in this report any change in the registrant\u8217?s internal control over financial reporting that occurred during\plain\li550\cf1\f51\fs20\ql the registrant\u8217?s most recent fiscal quarter (the registrant\u8217?s fourth fiscal quarter in the case of an annual report)\plain\li550\cf1\f51\fs20\ql that has materially affected, or is reasonably likely to materially affect, the registrant\u8217?s internal control over financial\plain\li550\cf1\f51\fs20\ql reporting; and\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\ql 5.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\ql The registrant\u8217?s other certifying officer and I have disclosed, based on our most recent evaluation of internal control\plain\li264\cf1\f51\fs20\ql over financial reporting, to the registrant\u8217?s auditors and the audit committee of the registrant\u8217?s board of directors\plain\li264\cf1\f51\fs20\ql (or persons performing the equivalent functions):\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql a.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting\plain\li550\cf1\f51\fs20\ql which are reasonably likely to adversely affect the registrant\u8217?s ability to record, process, summarize and report\plain\li550\cf1\f51\fs20\ql financial information; and\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql b.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql Any fraud, whether or not material, that involves management or other employees who have a significant role in the\plain\li550\cf1\f51\fs20\ql registrant\u8217?s internal control over financial reporting.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Date: August\~9, 2017\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clbrdrb\brdrs\brdrcf1\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql /s/ Douglas A. Treco\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clbrdrb\brdrs\brdrcf1\cellx5400\cellx10800\trrh248\row}}}
{\trowd\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql Douglas A. Treco, Ph.D.\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5400\cellx10800\trrh248\row}}}
{\trowd\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql President and Chief Executive Officer\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5400\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart doc_1_3}{\*\bkmkend doc_1_3}\par\pard\plain\cf1\f51\fs20\b\qr Exhibit\~31.2\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO\par\pard\plain\cf1\f51\fs20\b\qc RULE 13a-14(a)\~/ RULE 15d-14(a)\~OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql I, David C. Lubner, certify that:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\ql 1.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\ql I have reviewed this Quarterly Report on Form\~10-Q of Ra Pharmaceuticals,\~Inc.;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\ql 2.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\ql Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact\plain\li264\cf1\f51\fs20\ql necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading\plain\li264\cf1\f51\fs20\ql with respect to the period covered by this report;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\ql 3.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\ql Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all\plain\li264\cf1\f51\fs20\ql material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods\plain\li264\cf1\f51\fs20\ql presented in this report;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\ql 4.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\ql The registrant\u8217?s other certifying officer and I are responsible for establishing and maintaining disclosure controls and\plain\li264\cf1\f51\fs20\ql procedures (as defined in Exchange Act Rules\~13a-15(e)\~and 15d-15(e)) for the registrant and have:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql a.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed\plain\li550\cf1\f51\fs20\ql under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,\plain\li550\cf1\f51\fs20\ql is made known to us by others within those entities, particularly during the period in which this report is being prepared;\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql b.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql (Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql c.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql Evaluated the effectiveness of the registrant\u8217?s disclosure controls and procedures and presented in this report our\plain\li550\cf1\f51\fs20\ql conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this\plain\li550\cf1\f51\fs20\ql report based on such evaluation; and\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql d.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql Disclosed in this report any change in the registrant\u8217?s internal control over financial reporting that occurred during\plain\li550\cf1\f51\fs20\ql the registrant\u8217?s most recent fiscal quarter (the registrant\u8217?s fourth fiscal quarter in the case of an annual report)\plain\li550\cf1\f51\fs20\ql that has materially affected, or is reasonably likely to materially affect, the registrant\u8217?s internal control over financial\plain\li550\cf1\f51\fs20\ql reporting; and\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li264\fi-264\cf1\f51\fs20\ql 5.\plain\li264\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li264\cf1\f51\fs20\ql The registrant\u8217?s other certifying officer and I have disclosed, based on our most recent evaluation of internal control\plain\li264\cf1\f51\fs20\ql over financial reporting, to the registrant\u8217?s auditors and the audit committee of the registrant\u8217?s board of directors\plain\li264\cf1\f51\fs20\ql (or persons performing the equivalent functions):\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql a.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting\plain\li550\cf1\f51\fs20\ql which are reasonably likely to adversely affect the registrant\u8217?s ability to record, process, summarize and report\plain\li550\cf1\f51\fs20\ql financial information; and\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql b.\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql Any fraud, whether or not material, that involves management or other employees who have a significant role in the\plain\li550\cf1\f51\fs20\ql registrant\u8217?s internal control over financial reporting.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Dated: August\~9, 2017\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clbrdrb\brdrs\brdrcf1\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql /s/ David C. Lubner\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clbrdrb\brdrs\brdrcf1\cellx5400\cellx10800\trrh248\row}}}
{\trowd\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql David C. Lubner\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5400\cellx10800\trrh248\row}}}
{\trowd\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql Executive Vice President and Chief Financial Officer\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5400\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page{\*\bkmkstart doc_1_4}{\*\bkmkend doc_1_4}\par\pard\plain\cf1\f51\fs20\b\qr Exhibit\~32.1\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\b\qc CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION\~1350,\par\pard\plain\cf1\f51\fs20\b\qc AS ADOPTED PURSUANT TO\par\pard\plain\cf1\f51\fs20\b\qc SECTION\~906 OF THE SARBANES-OXLEY ACT OF 2002\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql In connection with this Quarterly Report on Form\~10-Q of Ra Pharmaceuticals,\~Inc. (the \u8220?Company\u8221?) for the period\plain\cf1\f51\fs20\ql ended June\~30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the \u8220?Report\u8221?), each\plain\cf1\f51\fs20\ql of the undersigned, Douglas A. Treco, Ph.D., President and Chief Executive Officer of the Company, and David C. Lubner,\plain\cf1\f51\fs20\ql Executive Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. (section) 1350, as\plain\cf1\f51\fs20\ql adopted pursuant to (section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of his or her knowledge:\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql (1)\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql The Report fully complies with the requirements of Section\~13(a)\~or 15(d)\~of the Securities Exchange Act of 1934; and\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\li550\fi-264\cf1\f51\fs20\ql (2)\plain\li550\cf1\f51\fs6\ql \~\~\~\~\~\~\~\~\plain\li550\cf1\f51\fs20\ql The information contained in the Report fairly presents, in all material respects, the financial condition and results of\plain\li550\cf1\f51\fs20\ql operations of the Company.\par\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\cf1\f51\fs20\ql Dated: August\~9, 2017\par\pard\plain\cf1\f51\fs20\ql \~
\par\pard\plain
{\trowd\clbrdrb\brdrs\brdrcf1\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql /s/ Douglas A. Treco\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clbrdrb\brdrs\brdrcf1\cellx5400\cellx10800\trrh248\row}}}
{\trowd\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql Douglas A. Treco, Ph.D.\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5400\cellx10800\trrh248\row}}}
{\trowd\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql President and Chief Executive Officer\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5400\cellx10800\trrh248\row}}}
{\trowd\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql \~\cell\pard\plain\intbl\cf1\f51\fs20\ql \~\cell{
{\trowd\cellx5400\cellx10800\trrh248\row}}}
{\trowd\clbrdrb\brdrs\brdrcf1\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql /s/ David C. Lubner\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\clbrdrb\brdrs\brdrcf1\cellx5400\cellx10800\trrh248\row}}}
{\trowd\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql David C. Lubner\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5400\cellx10800\trrh248\row}}}
{\trowd\cellx5400\cellx10800\trrh248
\pard\plain\intbl\cf1\f51\fs20\ql Executive Vice President and Chief Financial Officer\cell\pard\plain\intbl\cf1\f51\fs2\ql \~\cell{
{\trowd\cellx5400\cellx10800\trrh248\row}}}\pard\plain\cf1\f51\fs20\ql \~\par\pard\plain\f0\fs4\par\pard\plain\f0\fs2\brdrt\brdrs\brdrw15\brdrcf2\brdrsp0\par\pard\plain\f0\fs4\par
\page}